Trametinib Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

243

Total Trials

Recruiting

Completed

35,775

Total Enrollment

States

Trametinib Evidence & Publications

254 peer-reviewed publications + per-arm primary-outcome data from 12 pivotal trials.

See published evidence →

Trametinib Clinical Trials

Sortable list of all 243 Trametinib trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

What Is Trametinib?

Trametinib is an FDA-approved medication for adult patients with melanoma (a type of skin cancer) or lung cancer, and in children with glioma (a type of brain tumor). It is also approved for the treatment of metastatic melanoma. Trametinib is a type of targeted therapy known as a MEK inhibitor. It works by blocking specific proteins in the body called MEK1 and MEK2, which are part of a pathway that can become overactive in certain cancers, leading to uncontrolled cell growth. By inhibiting these proteins, trametinib helps to slow or stop the growth of cancer cells.

Beyond its approved uses, trametinib is being investigated for a variety of other cancers and conditions, often in combination with other drugs. These investigational uses include other types of cancer with specific genetic mutations, such as those in the Ras/MAPK pathway.

Uses and Conditions Under Study

Trametinib has been studied in a total of 243 trials involving 35,775 participants. These studies cover a range of conditions, primarily focusing on various cancers.

Melanoma: Trametinib is extensively studied for melanoma, including metastatic and unresectable forms. It is approved for metastatic melanoma and is often used in combination with other targeted therapies for melanoma with specific genetic mutations like BRAF V600. There are 45 trials for melanoma, 13 trials for metastatic melanoma, and 8 trials for unresectable melanoma.
Colorectal Cancer: This medication is being investigated for colorectal cancer, particularly in cases with KRAS, NRAS, or RAS mutations, or microsatellite stable (MSS) colorectal cancer. The drug aims to target the overactive signaling pathways often found in these tumors. There are 9 trials for colorectal cancer.
Other Cancers: Trametinib is also under investigation for a broad spectrum of other cancers. This includes general cancer (21 trials), advanced malignant solid neoplasms (8 trials), refractory malignant solid neoplasms (8 trials), hematopoietic and lymphoid cell neoplasms (6 trials), multiple myeloma (6 trials), and metastatic malignant solid neoplasms (6 trials). It is also being studied in lung cancer, glioma, pancreatic cancer, biliary tract cancer, non-small cell lung cancer (NSCLC), Erdheim-Chester Disease (ECD), and various other advanced or rare cancers.
Vascular Anomalies: Trametinib is being assessed for its effectiveness and safety in patients with Ras/MAPK pathway-driven vascular anomalies. This indicates its potential role in conditions where this specific cellular pathway is disrupted.

Dosing

Trametinib is available in oral tablets and has also been studied as a powder for oral solution. It is typically taken by mouth (PO).

In adult patients, a common investigational dose for trametinib has been 2 mg once daily. However, various strengths and regimens have been explored in clinical trials, including 0.5 mg, 1 mg, and 1.5 mg daily doses.

For pediatric patients, weight-based doses have been investigated, such as 0.0125 mg/kg/day, 0.025 mg/kg/day, 0.032 mg/kg/day, and 0.04 mg/kg/day. Trametinib is frequently studied in combination with other anticancer drugs, such as dabrafenib, nivolumab, or pembrolizumab, where the dosing of each agent is carefully determined. The specific dose and regimen depend on the condition being treated and whether it is used as a single agent or in combination therapy.

Side Effects

In clinical trials involving 1650 to 1652 patients, the most common side effects reported with Trametinib, compared to placebo, included:

Fever (pyrexia): 56.1% of patients on Trametinib experienced fever, compared to 29.3% on placebo.
Fatigue: 36.6% on Trametinib vs 29.4% on placebo.
Nausea: 34.4% on Trametinib vs 25.0% on placebo.
Headache: 31.9% on Trametinib vs 25.5% on placebo.
Diarrhea: 31.8% on Trametinib vs 18.4% on placebo.
Chills: 29.8% on Trametinib vs 13.8% on placebo.
Joint pain (arthralgia): 28.9% on Trametinib vs 23.5% on placebo.
Rash: 28.5% on Trametinib vs 18.4% on placebo.

Clinical Trial Results

Non-Small Cell Lung Cancer (NSCLC)

A study (NCT01336634) investigated Trametinib in combination with Dabrafenib for metastatic BRAF V600E mutation-positive NSCLC. Key findings included:

Median Overall Survival (OS) was 18.2 months for patients receiving the combination therapy (Cohort B) and 17.3 months for treatment-naive patients (Cohort C), compared to 12.7 months for Dabrafenib monotherapy (Cohort A).
Median Progression-Free Survival (PFS) was 10.2 months for the combination therapy (Cohort B) and 10.8 months for treatment-naive patients (Cohort C), compared to 5.4 months for Dabrafenib monotherapy (Cohort A).
The Overall Response Rate (ORR) was 39% for the combination therapy (Cohort B) and 44.2% for treatment-naive patients (Cohort C), compared to 25.5% for Dabrafenib monotherapy (Cohort A).

Melanoma

Several studies evaluated Trametinib, often in combination with Dabrafenib, for melanoma.

In a study (NCT01584648) comparing Dabrafenib plus Trametinib to Dabrafenib plus placebo in BRAF-mutant melanoma:

Median Overall Survival (OS) was 25.8 months for the combination therapy, compared to 18.7 months for Dabrafenib plus placebo.
Median Progression-Free Survival (PFS) was 10.2 months for the combination therapy, compared to 8.8 months for Dabrafenib plus placebo.
The Objective Response Rate (ORR) was 71.9% for the combination therapy, compared to 55.1% for Dabrafenib plus placebo.

Another study (NCT01597908) compared Dabrafenib plus Trametinib to Vemurafenib alone in unresectable or metastatic BRAF V600E/K cutaneous melanoma:

Median Overall Survival (OS) was 26.0 months for the combination therapy, compared to 17.8 months for Vemurafenib.
Median Progression-Free Survival (PFS) was 12.1 months for the combination therapy, compared to 7.3 months for Vemurafenib.
The Overall Response Rate (ORR) was 68% for the combination therapy, compared to 53% for Vemurafenib.

For adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma, a study (NCT01682083) found that the median Relapse-free Survival (RFS) was not reached in patients receiving Dabrafenib and Trametinib combination therapy, while it was 16.6 months for those on placebo. This indicates a longer period without relapse for patients on the combination therapy.

In a study (NCT01701037) evaluating Dabrafenib with Trametinib before surgery for locally or regionally advanced melanoma, 83.3% of patients showed a clinical tumor response (greater than 30% reduction in tumor volume) by Day 14. For patients with intrinsic resistance to B-RAF targeted therapy, a median tumor volume reduction of 18.0% was observed between Day 14 and Day 28.

Currently Recruiting Trials

Trametinib is currently being investigated in 39 clinical trials for a variety of cancers and other conditions, often in combination with other therapies. These studies aim to understand its safety and effectiveness, and how it might improve outcomes for patients. One such study, NCT07477457, is a Phase 2 trial enrolling 45 participants with newly diagnosed or relapsed metastatic osteosarcoma. Sponsored by Memorial Sloan Kettering Cancer Center, it explores whether adding trametinib, gefitinib, disulfiram, and sunitinib to standard chemotherapy is more effective than chemotherapy alone. For patients with low-grade gliomas that have a BRAF V600 gene mutation, the University of California, San Francisco is sponsoring NCT07110246, a Phase 2 trial with an enrollment target of 96. This study investigates de-escalating dabrafenib and trametinib treatment. In the realm of thyroid cancer, NCT06475989 is a Phase 3 trial by ECOG-ACRIN Cancer Research Group, aiming for 264 participants. It compares dabrafenib and trametinib combination therapy against cabozantinib for refractory differentiated thyroid cancer with a BRAF V600E mutation. Another study, NCT06079333, is a Phase 2 trial from Leiden University Medical Center for 20 participants with BRAF-mutated anaplastic thyroid cancer, evaluating neo-adjuvant and adjuvant BRAF/MEK inhibition. Pediatric patients are also included in research. Cook Children's Health Care System is running NCT06582745, a Phase 2 trial for 75 children with newly or recently diagnosed Langerhans Cell Histiocytosis, to assess trametinib's safety and effectiveness. Similarly, the Therapeutic Advances in Childhood Leukemia Consortium is conducting NCT05849662, a Phase 1/Phase 2 study for 58 patients with newly diagnosed juvenile myelomonocytic leukemia, testing trametinib combined with azacitidine. For those with advanced solid tumors, Vividion Therapeutics, Inc. is sponsoring NCT06804824, a Phase 1 study enrolling 220 participants to evaluate a new agent, VVD-159642, alone and in combination with sotorasib or trametinib.

Where to Participate

Clinical trials involving trametinib are globally accessible, with study sites spanning across numerous countries. In the United States, participation is available in 45 states, across 358 cities, and at 551 different locations. The top cities for participation include:

New York, New York (12 sites)
Chicago, Illinois (9 sites)
Milwaukee, Wisconsin (8 sites)
St Louis, Missouri (8 sites)
San Francisco, California (8 sites)
Miami, Florida (7 sites)
Anchorage, Alaska (7 sites)
Ann Arbor, Michigan (7 sites)
Nashville, Tennessee (6 sites)
Baltimore, Maryland (6 sites)

These trials are open to a broad age range, from 0-100 years, and welcome participants of all genders. Healthy volunteers are not eligible for these studies, but children are able to participate in many of the trials.

Development Timeline

The journey of trametinib in clinical research began on August 31, 2010, with the latest trial starting on April 24, 2026. Since its inception, trametinib has been investigated in a total of 243 trials, enrolling over 35,775 participants. Early in its development, trametinib was explored for conditions such as IBS-C and hyperphosphatemia. However, its pipeline quickly expanded, with a significant focus on various cancers. The largest number of trials, 108, are in Phase 2, followed by 64 in Phase 1, indicating a robust ongoing investigation into new applications and combinations. Major sponsors driving this research include Novartis Pharmaceuticals with 32 trials and the National Cancer Institute (NCI) with 31 trials, alongside GlaxoSmithKline and prominent academic centers. Over time, the scope of conditions studied has broadened considerably. Initially, the focus shifted to metastatic melanoma, then expanded to include colorectal cancer, various solid tumors, and hematopoietic and lymphoid cell neoplasms. More recently, trametinib has been extensively studied for thyroid cancer, low-grade and high-grade gliomas, and Langerhans Cell Histiocytosis, often targeting specific genetic mutations like BRAF V600E. This evolution reflects a growing understanding of trametinib's mechanism of action and its potential to address a diverse range of challenging diseases.

Trametinib Development Timeline

Clinical trial activity from 2010 to 2026.

2026

NCT07468071PHASE1/PHASE2recruiting

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

40 enrolled

NCT07477457PHASE2recruiting

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

45 enrolled

NCT07440290PHASE2/PHASE3not yet recruiting

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

30 enrolled

2025

NCT05275374PHASE1/PHASE2not yet recruiting

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

221 enrolled

NCT07419932recruiting

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

120 enrolled

NCT07110246PHASE2recruiting

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

96 enrolled

NCT07549646PHASE2active not recruiting

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

45 enrolled

NCT07092670recruiting

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

270 enrolled

NCT07072403PHASE1/PHASE2active not recruiting

Trametinib Treatment for Complicated Vascular Anomalies

20 enrolled

NCT07010393PHASE4not yet recruiting

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

NCT07022834PHASE2recruiting

Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

20 enrolled

NCT06962254PHASE1recruiting

Imatinib and Trametinib for KRAS-mutated Solid Tumor

10 enrolled

NCT06712875PHASE1/PHASE2recruiting

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

27 enrolled

NCT06119789PHASE2recruiting

Precision Cancer Therapy in Rare Cancers

96 enrolled

NCT06819605PHASE2/PHASE3not yet recruiting

Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma

46 enrolled

NCT06967155PHASE2active not recruiting

A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

23 enrolled

NCT06804824PHASE1recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

220 enrolled

2024

NCT06739395PHASE2recruiting

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

NCT06563999PHASE2recruiting

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

120 enrolled

NCT05849662PHASE1/PHASE2recruiting

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

58 enrolled

NCT06475989PHASE3recruiting

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

264 enrolled

NCT06532149recruiting

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

80 enrolled

NCT06555237PHASE2recruiting

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

40 enrolled

NCT06456138PHASE1/PHASE2not yet recruiting

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

60 enrolled

NCT06582745PHASE2recruiting

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

75 enrolled

NCT06346067PHASE3active not recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

78 enrolled

NCT06362694PHASE2recruiting

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

10 enrolled

NCT06054191PHASE2not yet recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

40 enrolled

NCT06098872PHASE2withdrawn

Pilot Study on Trametinib for Surgical Unruptured AVMs

0 enrolled

2023

NCT05658640PHASE1/PHASE2recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

26 enrolled

NCT05988697not yet recruiting

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

36 enrolled

NCT05525273PHASE2recruiting

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

25 enrolled

NCT05874414PHASE1/PHASE2recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

74 enrolled

NCT05907304PHASE1active not recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

86 enrolled

NCT05876806PHASE2unknown

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

30 enrolled

NCT05518110PHASE2terminated

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

20 enrolled

NCT05440942PHASE1completed

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

28 enrolled

NCT05677373PHASE1/PHASE2withdrawn

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

0 enrolled

NCT06653517PHASE2recruiting

Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

12 enrolled

NCT06079333PHASE2recruiting

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

20 enrolled

2022

NCT05668585PHASE1completed

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

89 enrolled

NCT04454476PHASE1active not recruiting

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

15 enrolled

NCT05358249PHASE1/PHASE2active not recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

74 enrolled

NCT05372354PHASE1/PHASE2recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

260 enrolled

NCT05435846PHASE1terminated

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

3 enrolled

NCT05182931PHASE2unknown

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

80 enrolled

NCT04903119PHASE1recruiting

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

30 enrolled

NCT05180825PHASE2recruiting

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

134 enrolled

NCT04566133PHASE2terminated

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

2 enrolled

NCT05260684completed

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

716 enrolled

2021

NCT05159245PHASE2recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

250 enrolled

NCT04961619completed

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

39 enrolled

NCT02645149PHASE2completed

Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

216 enrolled

NCT04940052PHASE3active not recruiting

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

153 enrolled

NCT05616923PHASE1completed

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

12 enrolled

NCT05048134PHASE1terminated

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

13 enrolled

NCT04547946completed

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

3 enrolled

NCT05714371completed

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

618 enrolled

NCT05171374unknown

pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

500 enrolled

NCT05071183PHASE1/PHASE2terminated

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

9 enrolled

NCT04801966NAterminated

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

3 enrolled

NCT04557956PHASE1/PHASE2active not recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

16 enrolled

NCT04967079PHASE1completed

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

33 enrolled

NCT04675710PHASE2active not recruiting

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

30 enrolled

NCT04892017PHASE1terminated

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

91 enrolled

NCT04527549PHASE2terminated

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

5 enrolled

NCT06482086PHASE2recruiting

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

75 enrolled

NCT04943224PHASE2recruiting

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

12 enrolled

NCT05299580PHASE2withdrawn

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

0 enrolled

NCT04739566PHASE2withdrawn

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

0 enrolled

NCT04803318PHASE2recruiting

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

100 enrolled

2020

NCT04666272active not recruiting

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

78 enrolled

NCT04554680PHASE2unknown

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

5 enrolled

NCT04485559PHASE1recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

50 enrolled

NCT04258046PHASE2completed

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

25 enrolled

NCT04417621PHASE2active not recruiting

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

NCT03975231PHASE1recruiting

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

6 enrolled

NCT04544202no longer available

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

0 enrolled

NCT04544111PHASE2active not recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

NCT04452877PHASE2completed

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

40 enrolled

NCT04489433no longer available

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

0 enrolled

NCT04294160PHASE1terminated

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

122 enrolled

NCT04487106PHASE2completed

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

21 enrolled

NCT05611229completed

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

1,975 enrolled

NCT04326283PHASE1/PHASE2terminated

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

23 enrolled

NCT03878524PHASE1terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

2 enrolled

NCT03919071PHASE2active not recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

58 enrolled

NCT04310397PHASE2terminated

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

4 enrolled

NCT04116541PHASE2recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

455 enrolled

NCT04238624PHASE2active not recruiting

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

NCT04201457PHASE1/PHASE2active not recruiting

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

57 enrolled

NCT06195228PHASE4recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

800 enrolled

2019

NCT04185883PHASE1active not recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

610 enrolled

NCT03975829PHASE4active not recruiting

Pediatric Long-Term Follow-up and Rollover Study

165 enrolled

NCT04111458PHASE1active not recruiting

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

71 enrolled

NCT03784014PHASE3completed

Molecular Profiling of Advanced Soft-tissue Sarcomas

603 enrolled

NCT03979651NAcompleted

MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma

29 enrolled

NCT03631953PHASE1recruiting

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas

25 enrolled

NCT03899155PHASE2recruiting

Pan Tumor Rollover Study

1,500 enrolled

NCT03944356completed

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

232 enrolled

NCT03972046PHASE2withdrawn

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

0 enrolled

NCT03741101PHASE2unknown

Treatment of NF1-related Plexiform Neurofibroma With Trametinib

15 enrolled

NCT03272464PHASE1terminated

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

1 enrolled

NCT03825289PHASE1terminated

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

25 enrolled

NCT04059224PHASE2completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

45 enrolled

NCT03794297PHASE2withdrawn

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

0 enrolled

2018

NCT03714958PHASE1completed

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

12 enrolled

NCT03668431PHASE2unknown

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

25 enrolled

NCT03704688PHASE1/PHASE2completed

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

12 enrolled

NCT03455764PHASE1/PHASE2completed

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

6 enrolled

NCT03190915PHASE2active not recruiting

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

10 enrolled

NCT02672358PHASE2withdrawn

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

0 enrolled

NCT03551626PHASE3completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

552 enrolled

NCT03363217PHASE2active not recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

114 enrolled

NCT04303403PHASE1unknown

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

48 enrolled

NCT03580382PHASE1/PHASE2terminated

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

3 enrolled

NCT03543306PHASE2unknown

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

27 enrolled

NCT03501368PHASE1completed

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

27 enrolled

NCT03299088PHASE1completed

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

15 enrolled

NCT03563729PHASE2recruiting

Melanoma Metastasized to the Brain and Steroids

80 enrolled

NCT03516214PHASE1completed

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

18 enrolled

NCT03317119PHASE1completed

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

26 enrolled

NCT03428126PHASE2completed

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

29 enrolled

NCT03434262PHASE1completed

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

68 enrolled

NCT03232892PHASE2terminated

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

1 enrolled

NCT02974803PHASE2terminated

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

6 enrolled

NCT04619316PHASE2unknown

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

70 enrolled

NCT03225664PHASE1/PHASE2active not recruiting

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled

NCT03377361PHASE1/PHASE2completed

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

325 enrolled

NCT02881242PHASE2active not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

14 enrolled

NCT03333343PHASE1active not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

NCT03754179PHASE1/PHASE2unknown

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

63 enrolled

2017

NCT03087071PHASE2active not recruiting

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

59 enrolled

NCT03386071no longer available

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

0 enrolled

NCT03340506PHASE4recruiting

Dabrafenib and/or Trametinib Rollover Study

100 enrolled

NCT02684058PHASE2completed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

151 enrolled

NCT03244956PHASE2completed

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

40 enrolled

NCT03149029PHASE2active not recruiting

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

16 enrolled

NCT03266159PHASE2withdrawn

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors

0 enrolled

NCT02858921PHASE2unknown

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

60 enrolled

NCT03352947PHASE2completed

Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma

79 enrolled

NCT03065387PHASE1active not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

NCT03087448PHASE1terminated

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

9 enrolled

NCT02367859PHASE2completed

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

1 enrolled

NCT03088176PHASE1unknown

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

4 enrolled

NCT03091257PHASE1active not recruiting

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

30 enrolled

NCT03148275PHASE2completed

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

44 enrolled

NCT02447939PHASE1withdrawn

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

0 enrolled

NCT02939846PHASE1withdrawn

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

0 enrolled

NCT03085056EARLY_PHASE1active not recruiting

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

13 enrolled

NCT03076164PHASE1/PHASE2completed

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

24 enrolled

NCT02974725PHASE1terminated

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

241 enrolled

NCT02967692PHASE3terminated

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

568 enrolled

NCT02872259PHASE1/PHASE2completed

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

74 enrolled

NCT02342600PHASE2withdrawn

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

0 enrolled

NCT03026517PHASE1completed

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

18 enrolled

2016

NCT02910700PHASE2active not recruiting

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

NCT02915666PHASE1withdrawn

A Clinical Trial of Patients With Melanoma

0 enrolled

NCT02705963PHASE1completed

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

19 enrolled

NCT02925234PHASE2recruiting

The Drug Rediscovery Protocol (DRUP Trial)

1,550 enrolled

NCT02642042PHASE2active not recruiting

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

60 enrolled

NCT02703571PHASE1terminated

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

95 enrolled

NCT02428270PHASE2completed

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

16 enrolled

NCT02693535PHASE2recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

4,200 enrolled

NCT02292732PHASE1withdrawn

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

0 enrolled

NCT04439318PHASE2active not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled

NCT04439357PHASE2active not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled

NCT02625337PHASE2unknown

Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients

32 enrolled

NCT04439292PHASE2active not recruiting

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

44 enrolled

2015

NCT02300935PHASE1withdrawn

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

0 enrolled

NCT02410863PHASE2terminated

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

10 enrolled

NCT02580708PHASE1/PHASE2terminated

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

7 enrolled

NCT02224781PHASE3active not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled

NCT02538627PHASE1terminated

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

5 enrolled

NCT02357732PHASE1withdrawn

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

0 enrolled

NCT02465060PHASE2active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

6,452 enrolled

NCT04439279PHASE2active not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

35 enrolled

NCT02399943PHASE2completed

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

14 enrolled

NCT02392871PHASE1/PHASE2completed

Radiotherapy & Combi in Metastatic Melanoma

10 enrolled

NCT02416232no longer available

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

0 enrolled

NCT02140840PHASE2withdrawn

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

0 enrolled

NCT02258607PHASE1terminated

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

21 enrolled

NCT02439411completed

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

135 enrolled

NCT02292173PHASE1completed

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

17 enrolled

NCT02296112PHASE2completed

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

9 enrolled

NCT02124772PHASE1/PHASE2completed

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

139 enrolled

2014

NCT02110355PHASE1completed

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

31 enrolled

NCT02281760PHASE2completed

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

9 enrolled

NCT02296996PHASE2completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

25 enrolled

NCT02257424PHASE1/PHASE2completed

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

50 enrolled

NCT02231775PHASE2active not recruiting

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

NCT02230553PHASE1/PHASE2completed

Lapatinib Plus Trametinib in KRAS Mutant NSCLC

35 enrolled

NCT01972347PHASE2active not recruiting

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

35 enrolled

NCT02143050PHASE1/PHASE2withdrawn

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

0 enrolled

NCT01990196PHASE2active not recruiting

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

45 enrolled

NCT02196181PHASE2active not recruiting

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

280 enrolled

NCT02152995PHASE2active not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

34 enrolled

NCT02138292PHASE1completed

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

27 enrolled

NCT02097225PHASE1terminated

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

22 enrolled

NCT02130466PHASE1/PHASE2completed

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

184 enrolled

NCT02015117PHASE1active not recruiting

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

10 enrolled

NCT02065063PHASE1completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

28 enrolled

NCT02101788PHASE2/PHASE3completed

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

260 enrolled

NCT01978236PHASE2terminated

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

6 enrolled

NCT02016729PHASE1completed

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

36 enrolled

NCT02079740PHASE1/PHASE2active not recruiting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

96 enrolled

NCT01989585PHASE1/PHASE2active not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

75 enrolled

NCT02083354PHASE2completed

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

77 enrolled

NCT02034110PHASE2completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

206 enrolled

NCT02070549PHASE1completed

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

46 enrolled

NCT02042443PHASE2completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

53 enrolled

NCT02039947PHASE2completed

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

127 enrolled

NCT01827384PHASE2completed

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

208 enrolled

2013

NCT02027961PHASE1completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

68 enrolled

NCT01979523PHASE2active not recruiting

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

42 enrolled

NCT01938443PHASE1completed

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

34 enrolled

NCT02314143PHASE2terminated

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

48 enrolled

NCT01958112PHASE2terminated

GSK1120212+GSK2141795 for Cervical Cancer

14 enrolled

NCT01907815PHASE2terminated

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

24 enrolled

NCT01938456PHASE1withdrawn

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

0 enrolled

NCT01989598PHASE2completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

NCT01912625PHASE1terminated

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

16 enrolled

NCT01902173PHASE1/PHASE2completed

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

27 enrolled

NCT01964924PHASE2completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

37 enrolled

NCT01935973PHASE1completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

26 enrolled

NCT01943864PHASE2completed

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

20 enrolled

NCT01941927PHASE2completed

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

20 enrolled

NCT01940809PHASE1terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

15 enrolled

NCT01928940PHASE2completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

12 enrolled

NCT01721603PHASE2terminated

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

2 enrolled

NCT01726738PHASE2completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

17 enrolled

NCT01767454PHASE1completed

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

38 enrolled

NCT01701037PHASE2terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

13 enrolled

NCT01682083PHASE3completed

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

870 enrolled

2012

NCT01750918PHASE1/PHASE2completed

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

166 enrolled

NCT01740648PHASE1completed

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

19 enrolled

NCT01723202PHASE2completed

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

53 enrolled

NCT01647659PHASE1completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

18 enrolled

NCT01597908PHASE3completed

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

704 enrolled

NCT01584648PHASE3completed

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

423 enrolled

2011

NCT01336634PHASE2completed

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

177 enrolled

2010

NCT01192165PHASE1completed

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

169 enrolled

NCT01287546PHASE1completed

A Study of LY2875358 in Participants With Advanced Cancer

117 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Melanoma	NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221
	NCT07092670	MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.	recruiting	N/A	270
	NCT05668585	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	completed	PHASE1	89
	NCT05260684	Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US	completed	N/A	716
	NCT04961619	Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.	completed	N/A	39
	NCT02645149	Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma	completed	PHASE2	216
	NCT05714371	Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma	completed	N/A	618
	NCT05171374	pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	unknown	N/A	500
	NCT05299580	"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"	withdrawn	PHASE2	0
	NCT04666272	Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection	active not recruiting	N/A	78
	NCT04417621	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	active not recruiting	PHASE2	134
	NCT03944356	BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	completed	N/A	232
	NCT03272464	INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.	terminated	PHASE1	1
	NCT03455764	MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	completed	PHASE1/PHASE2	6
	NCT03580382	Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma	terminated	PHASE1/PHASE2	3
	NCT03501368	Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma	completed	PHASE1	27
	NCT02974803	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	terminated	PHASE2	6
	NCT03754179	Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma	unknown	PHASE1/PHASE2	63
	NCT03340506	Dabrafenib and/or Trametinib Rollover Study	recruiting	PHASE4	100
	NCT02858921	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	unknown	PHASE2	60
	NCT03352947	Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma	completed	PHASE2	79
	NCT03088176	Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma	unknown	PHASE1	4
	NCT02447939	Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma	withdrawn	PHASE1	0
	NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	terminated	PHASE1	241
	NCT02967692	A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma	terminated	PHASE3	568
	NCT02872259	BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma	completed	PHASE1/PHASE2	74
	NCT03026517	Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma	completed	PHASE1	18
	NCT02915666	A Clinical Trial of Patients With Melanoma	withdrawn	PHASE1	0
	NCT02300935	Study of Trametinib and Nab-paclitaxel in Patients With Melanoma	withdrawn	PHASE1	0
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
	NCT01972347	Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma	active not recruiting	PHASE2	35
	NCT02143050	Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients	withdrawn	PHASE1/PHASE2	0
	NCT02138292	A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma	completed	PHASE1	27
	NCT02130466	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	completed	PHASE1/PHASE2	184
	NCT02083354	Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma	completed	PHASE2	77
	NCT02027961	Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone	completed	PHASE1	68
	NCT02314143	Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib	terminated	PHASE2	48
	NCT01941927	Trametinib With GSK2141795 in BRAF Wild-type Melanoma	completed	PHASE2	20
	NCT01682083	Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).	completed	PHASE3	870
	NCT01597908	Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma	completed	PHASE3	704
	NCT01584648	A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma	completed	PHASE3	423
	NCT04544202	Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection	no longer available	N/A	0
	NCT04489433	Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma	no longer available	N/A	0
	NCT02416232	Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma	no longer available	N/A	0
Cancer	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221
	NCT05876806	Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations	unknown	PHASE2	30
	NCT04801966	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	terminated	NA	3
	NCT03899155	Pan Tumor Rollover Study	recruiting	PHASE2	1,500
	NCT03543306	Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation	unknown	PHASE2	27
	NCT02939846	Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours	withdrawn	PHASE1	0
	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
	NCT02292732	A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors	withdrawn	PHASE1	0
	NCT02124772	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	completed	PHASE1/PHASE2	139
	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
	NCT02065063	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	completed	PHASE1	28
	NCT02016729	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	completed	PHASE1	36
	NCT02083354	Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma	completed	PHASE2	77
	NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	completed	PHASE2	206
	NCT01938443	A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors	completed	PHASE1	34
	NCT01943864	A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers	completed	PHASE2	20
	NCT01750918	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	completed	PHASE1/PHASE2	166
	NCT01647659	Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation	completed	PHASE1	18
	NCT01336634	Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.	completed	PHASE2	177
	NCT01192165	Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel	completed	PHASE1	169
Metastatic Melanoma	NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	recruiting	PHASE1	30
	NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	PHASE1/PHASE2	16
	NCT05611229	Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden	completed	N/A	1,975
	NCT03149029	Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma	active not recruiting	PHASE2	16
	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02625337	Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients	unknown	PHASE2	32
	NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	PHASE3	267
	NCT02357732	Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib	withdrawn	PHASE1	0
	NCT02392871	Radiotherapy & Combi in Metastatic Melanoma	completed	PHASE1/PHASE2	10
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	PHASE1/PHASE2	75
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Colorectal Cancer	NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221
	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
	NCT03714958	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type	completed	PHASE1	12
	NCT04303403	Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma	unknown	PHASE1	48
	NCT03428126	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	completed	PHASE2	29
	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread	completed	PHASE1/PHASE2	325
	NCT02538627	Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib	terminated	PHASE1	5
	NCT02399943	A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	completed	PHASE2	14
	NCT02230553	Lapatinib Plus Trametinib in KRAS Mutant NSCLC	completed	PHASE1/PHASE2	35
Unresectable Melanoma	NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	terminated	PHASE2	5
	NCT03501368	Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma	completed	PHASE1	27
	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	PHASE3	267
	NCT02196181	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread	active not recruiting	PHASE2	280
	NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	PHASE1/PHASE2	75
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
	NCT01726738	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	completed	PHASE2	17
Advanced Malignant Solid Neoplasm	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
	NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50
	NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4
	NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35
	NCT02070549	Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	completed	PHASE1	46
	NCT01827384	MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations	completed	PHASE2	208
Refractory Malignant Solid Neoplasm	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
	NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50
	NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4
	NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35
	NCT02079740	Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	active not recruiting	PHASE1/PHASE2	96
Hematopoietic and Lymphoid Cell Neoplasm	NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50
	NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4
	NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
Multiple Myeloma	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT05372354	A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma	recruiting	PHASE1/PHASE2	260
	NCT03091257	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	active not recruiting	PHASE1	30
	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	recruiting	PHASE2	4,200
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT02140840	UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib	withdrawn	PHASE2	0
Metastatic Malignant Solid Neoplasm	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT02079740	Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	active not recruiting	PHASE1/PHASE2	96
	NCT02070549	Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	completed	PHASE1	46
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
Thyroid Cancer	NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221
	NCT07419932	Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer	recruiting	N/A	120
	NCT05182931	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	unknown	PHASE2	80
	NCT04554680	Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy	unknown	PHASE2	5
	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
	NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	PHASE2	16
Stage IIIC Cutaneous Melanoma AJCC v7	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02231775	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	active not recruiting	PHASE2	58
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Refractory Multiple Myeloma	NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50
	NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4
	NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35
Refractory Lymphoma	NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50
	NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4
	NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35
BRAF Gene Mutation	NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	recruiting	PHASE1	30
	NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	PHASE2	16
	NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	withdrawn	PHASE2	0
	NCT02367859	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	completed	PHASE2	1
	NCT03088176	Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma	unknown	PHASE1	4
Stage IV Cutaneous Melanoma AJCC v6 and v7	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02196181	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread	active not recruiting	PHASE2	280
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Malignant Melanoma	NCT04547946	Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)	completed	N/A	3
	NCT03551626	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes	completed	PHASE3	552
	NCT03563729	Melanoma Metastasized to the Brain and Steroids	recruiting	PHASE2	80
	NCT02410863	Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma	terminated	PHASE2	10
	NCT02296996	Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients	completed	PHASE2	25
Advanced Lymphoma	NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50
	NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4
	NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35
KRAS Gene Mutation	NCT03704688	Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer	completed	PHASE1/PHASE2	12
	NCT03299088	Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations	completed	PHASE1	15
	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
	NCT02642042	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	active not recruiting	PHASE2	60
Stage III Cutaneous Melanoma AJCC v7	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02196181	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread	active not recruiting	PHASE2	280
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Recurrent Melanoma	NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	PHASE3	267
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT02296112	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	completed	PHASE2	9
	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Anaplastic Thyroid Cancer	NCT06362694	Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	recruiting	PHASE2	10
	NCT06079333	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)	recruiting	PHASE2	20
	NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	PHASE2	16
	NCT03085056	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	active not recruiting	EARLY_PHASE1	13
Non-small Cell Lung Cancer	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
	NCT04892017	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors	terminated	PHASE1	91
	NCT03232892	Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer	terminated	PHASE2	1
	NCT03087448	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	terminated	PHASE1	9
	NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	terminated	PHASE1	241
	NCT02580708	Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer	terminated	PHASE1/PHASE2	7
	NCT02538627	Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib	terminated	PHASE1	5
Glioblastoma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Clinical Stage IV Cutaneous Melanoma AJCC v8	NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	PHASE1/PHASE2	16
	NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	terminated	PHASE2	5
	NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	PHASE3	267
	NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	PHASE1/PHASE2	75
Advanced Solid Tumors	NCT06804824	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors	recruiting	PHASE1	220
	NCT04185883	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	active not recruiting	PHASE1	610
	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	recruiting	PHASE2	4,200
	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
Stage IIIB Cutaneous Melanoma AJCC v7	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02231775	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	active not recruiting	PHASE2	58
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Anaplastic Ganglioglioma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Advanced Cancer	NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	not yet recruiting	N/A	36
	NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	recruiting	PHASE2	250
	NCT03714958	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type	completed	PHASE1	12
	NCT01287546	A Study of LY2875358 in Participants With Advanced Cancer	completed	PHASE1	117
Anaplastic Astrocytoma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Stage IIIA Cutaneous Melanoma AJCC v7	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Solid Tumours	NCT03266159	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors	withdrawn	PHASE2	0
	NCT01928940	Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)	completed	PHASE2	12
	NCT01767454	Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma	completed	PHASE1	38
Anaplastic Oligodendroglioma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Anaplastic Pleomorphic Xanthoastrocytoma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
BRAF V600K Mutation Present	NCT03975231	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	recruiting	PHASE1	6
	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
High Grade Glioma	NCT06712875	MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas	recruiting	PHASE1/PHASE2	27
	NCT04485559	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	recruiting	PHASE1	50
	NCT03340506	Dabrafenib and/or Trametinib Rollover Study	recruiting	PHASE4	100
Neoplasms	NCT06967155	A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer	active not recruiting	PHASE2	23
	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
	NCT01938443	A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors	completed	PHASE1	34
Ameloblastoma	NCT06819605	Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma	not yet recruiting	PHASE2/PHASE3	46
	NCT06653517	Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma	recruiting	PHASE2	12
	NCT02367859	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	completed	PHASE2	1
Colorectal Carcinoma	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread	completed	PHASE1/PHASE2	325
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Lung Non-Small Cell Carcinoma	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
	NCT02642042	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	active not recruiting	PHASE2	60
	NCT01912625	Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	terminated	PHASE1	16
Non-Small Cell Lung Cancer	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
	NCT04892017	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors	terminated	PHASE1	91
	NCT03232892	Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer	terminated	PHASE2	1
	NCT03087448	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	terminated	PHASE1	9
	NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	terminated	PHASE1	241
	NCT02580708	Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer	terminated	PHASE1/PHASE2	7
	NCT02538627	Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib	terminated	PHASE1	5
Non Small Cell Lung Cancer	NCT04967079	Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients	completed	PHASE1	33
	NCT03704688	Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer	completed	PHASE1/PHASE2	12
	NCT03340506	Dabrafenib and/or Trametinib Rollover Study	recruiting	PHASE4	100
Stage IV Melanoma	NCT04059224	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma	completed	PHASE2	45
	NCT02296112	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	completed	PHASE2	9
	NCT01726738	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	completed	PHASE2	17
NSCLC	NCT06054191	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	not yet recruiting	PHASE2	40
	NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	not yet recruiting	N/A	36
	NCT05668585	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	completed	PHASE1	89
Thyroid Gland Anaplastic Carcinoma	NCT04675710	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	active not recruiting	PHASE2	30
	NCT04739566	Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer	withdrawn	PHASE2	0
	NCT03975231	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	recruiting	PHASE1	6
Low-grade Glioma	NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	recruiting	PHASE2	96
	NCT04485559	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	recruiting	PHASE1	50
	NCT03363217	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	active not recruiting	PHASE2	114
Pleomorphic Xanthoastrocytoma	NCT05180825	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy	recruiting	PHASE2	134
	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Glioma	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Solid Tumor	NCT06739395	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	recruiting	PHASE2	300
	NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	recruiting	PHASE2	250
	NCT03340506	Dabrafenib and/or Trametinib Rollover Study	recruiting	PHASE4	100
BRAF V600 Mutation	NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221
	NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	recruiting	PHASE2	96
	NCT06054191	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	not yet recruiting	PHASE2	40
Solid Tumors	NCT05668585	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	completed	PHASE1	89
	NCT02705963	A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors	completed	PHASE1	19
	NCT02130466	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	completed	PHASE1/PHASE2	184
Clinical Stage III Cutaneous Melanoma AJCC v8	NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	PHASE3	267
	NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	PHASE1/PHASE2	75
Central Neurocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
KRAS Mutation-Related Tumors	NCT06456138	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	not yet recruiting	PHASE1/PHASE2	60
	NCT05071183	A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors	terminated	PHASE1/PHASE2	9
Metastatic Lung Non-Small Cell Carcinoma	NCT05435846	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	terminated	PHASE1	3
	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IV Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Stage III Melanoma	NCT04059224	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma	completed	PHASE2	45
	NCT01726738	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	completed	PHASE2	17
Nonsmall Cell Lung Cancer	NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221
	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
Colorectal Tumors	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread	completed	PHASE1/PHASE2	325
Follicular Thyroid Cancer	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
	NCT01723202	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	completed	PHASE2	53
Recurrent Plasma Cell Myeloma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
	NCT01989598	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma	completed	PHASE2	25
Poorly Differentiated Thyroid Gland Carcinoma	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Unresectable Solid Neoplasm	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT02070549	Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	completed	PHASE1	46
Recurrent Prostate Carcinoma	NCT02881242	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	active not recruiting	PHASE2	14
	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Langerhans Cell Histiocytosis (LCH)	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT07022834	Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children	recruiting	PHASE2	20
Oligodendroglioma, Childhood	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Oncology	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
	NCT02016729	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	completed	PHASE1	36
Oncology Patients	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
	NCT02016729	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	completed	PHASE1	36
Gangliocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Recurrent Thyroid Gland Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Ganglioglioma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Carcinoma, Non-Small-Cell Lung	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
	NCT04452877	A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC	completed	PHASE2	40
Chordoid Glioma of Third Ventricle	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Advanced Solid Tumor	NCT05071183	A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors	terminated	PHASE1/PHASE2	9
	NCT04892017	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors	terminated	PHASE1	91
Stage IVA Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Refractory Acute Myeloid Leukemia	NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21
	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Pancreatic Cancer	NCT05518110	PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer	terminated	PHASE2	20
	NCT02428270	A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	completed	PHASE2	16
Melanoma and Brain Metastases	NCT01978236	Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites	terminated	PHASE2	6
	NCT02039947	Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain	completed	PHASE2	127
Desmoplastic Infantile Astrocytoma and Ganglioglioma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Refractory Chronic Myelomonocytic Leukemia	NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21
	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Papillary Glioneuronal Tumor	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Stage IVB Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Papillary Thyroid Cancer	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
	NCT01723202	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	completed	PHASE2	53
Cholangiocarcinoma	NCT05874414	Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma	recruiting	PHASE1/PHASE2	74
	NCT04566133	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	terminated	PHASE2	2
Diffuse Astrocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Metastatic Solid Tumor	NCT05071183	A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors	terminated	PHASE1/PHASE2	9
	NCT04892017	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors	terminated	PHASE1	91
Recurrent Breast Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
BRAF V600E Mutation Present	NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22
	NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15
Refractory Myelodysplastic Syndrome	NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21
	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Acute Myeloid Leukemia	NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21
	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8	NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	terminated	PHASE2	5
	NCT04310397	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	terminated	PHASE2	4
Locally Advanced Melanoma	NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	terminated	PHASE2	5
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
Refractory Plasma Cell Myeloma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
	NCT01989598	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma	completed	PHASE2	25
Metastatic Malignant Neoplasm in the Brain	NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52
	NCT02015117	Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases	active not recruiting	PHASE1	10
Giant Cell Astrocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
BRAF V600E Mutation	NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	not yet recruiting	N/A	36
	NCT02281760	Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease	completed	PHASE2	9
Thyroid Neoplasms	NCT07419932	Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer	recruiting	N/A	120
	NCT07010393	Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study	not yet recruiting	PHASE4	335
Pilocytic Astrocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Dysplastic Gangliocytoma of Cerebrellum	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Tumors	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
Astrocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Vascular Anomalies	NCT07549646	24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs	active not recruiting	PHASE2	45
	NCT07072403	Trametinib Treatment for Complicated Vascular Anomalies	active not recruiting	PHASE1/PHASE2	20
Haematological Malignancy	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	recruiting	PHASE2	250
Erdheim-Chester Disease	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT03794297	Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations	withdrawn	PHASE2	0
Unresectable Malignant Solid Neoplasm	NCT02079740	Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	active not recruiting	PHASE1/PHASE2	96
	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
Stage IIIB Melanoma	NCT02296112	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	completed	PHASE2	9
	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Colorectal Neoplasms	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
Neurofibromatosis 1	NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	recruiting	PHASE1/PHASE2	58
	NCT03741101	Treatment of NF1-related Plexiform Neurofibroma With Trametinib	unknown	PHASE2	15
Neurofibromatosis Type 1	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	active not recruiting	PHASE2	10
Extraventricular Neurocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Advanced Malignancy	NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31
	NCT02016729	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	completed	PHASE1	36
Angiocentric Glioma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Lung Cancer Metastatic	NCT03543306	Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation	unknown	PHASE2	27
	NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24
Stage IIIC Melanoma	NCT02296112	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	completed	PHASE2	9
	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Recurrent Myelodysplastic Syndrome	NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21
	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Head and Neck Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Hematopoietic and Lymphoid System Neoplasm	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Hepatocellular Cancer	NCT02292173	Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer	completed	PHASE1	17
Hepatocellular Carcinoma	NCT04803318	Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors	recruiting	PHASE2	100
HER2/Neu Negative	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
High Grade Glioma (HGG) of the Brain With BRAF Aberration	NCT04201457	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	active not recruiting	PHASE1/PHASE2	57
Hilar Cholangiocarcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Histiocytosis	NCT04943224	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients	recruiting	PHASE2	12
Hormone-Resistant Prostate Cancer	NCT02881242	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	active not recruiting	PHASE2	14
Hurthle Cell Thyroid Neoplasia	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
Hurthle Cell Tumor	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
Hypogonadism, Male	NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	recruiting	N/A	80
Initial-onset Gastric Cancer	NCT04454476	Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor	active not recruiting	PHASE1	15
Insular Thyroid Cancer	NCT01723202	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	completed	PHASE2	53
Invasive Breast Carcinoma	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
JCML	NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	recruiting	PHASE1/PHASE2	58
JMML	NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	recruiting	PHASE1/PHASE2	58
Juvenile Myelomonocytic Leukemia	NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	active not recruiting	PHASE2	10
Kidney Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Kirsten Rat Sarcoma (KRAS) pG12C Mutation	NCT04185883	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	active not recruiting	PHASE1	610
KRAS G12C Mutant Solid Tumors	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
KRAS Wildtype	NCT02399943	A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	completed	PHASE2	14
Langerhans Cell Histiocytosis	NCT06582745	Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib	recruiting	PHASE2	75
Laryngeal Neoplasms	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Leukemia, Juvenile Myelomonocytic	NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	recruiting	PHASE1/PHASE2	58
Liver Cancer	NCT02292173	Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer	completed	PHASE1	17
Liver Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Localized Non-Resectable Adult Liver Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Locally Advanced Epithelioid Hemangioendothelioma	NCT03148275	Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery	completed	PHASE2	44
Locally Advanced Malignant Solid Neoplasm	NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer	NCT07468071	Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments	recruiting	PHASE1/PHASE2	40
Locally Advanced Pancreatic Adenocarcinoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Locally Advanced Thyroid Gland Carcinoma	NCT06482086	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer	recruiting	PHASE2	75
Low Grade Glioma	NCT06712875	MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas	recruiting	PHASE1/PHASE2	27
Low Grade Glioma (LGG) of Brain With BRAF Aberration	NCT04201457	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	active not recruiting	PHASE1/PHASE2	57
Low Grade Glioma of Brain	NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	recruiting	PHASE2	96
Low Grade Glioma of Brain With Neurofibromatosis Type 1	NCT04201457	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	active not recruiting	PHASE1/PHASE2	57
Lung Adenocarcinoma	NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24
Lung Cancer	NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24
Lung Cancer Stage III	NCT06563999	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.	recruiting	PHASE2	120
Lung Cancer Stage IV	NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24
Lung Cancer, Non-Small Cell	NCT01938456	Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer	withdrawn	PHASE1	0
Lung Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent	NCT05658640	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	recruiting	PHASE1/PHASE2	26
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory	NCT05658640	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	recruiting	PHASE1/PHASE2	26
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	NCT05658640	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	recruiting	PHASE1/PHASE2	26
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory	NCT05658640	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	recruiting	PHASE1/PHASE2	26
Lymphoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Lymphoma, Non-Hodgkin	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	recruiting	PHASE2	4,200
Lymphoproliferative Disorders	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Malignant Glioma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
Malignant Melanoma Stage IIIc	NCT02439411	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain	completed	N/A	135
Malignant Melanoma Stage IV	NCT02439411	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain	completed	N/A	135
Malignant Neoplasm	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Malignant Neoplasms of Digestive Organs	NCT03428126	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	completed	PHASE2	29
Malignant Solid Neoplasm	NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	PHASE1/PHASE2	75
Malignant Solid Tumor	NCT04116541	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.	recruiting	PHASE2	455
Malignant Uterine Corpus Neoplasm	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Malignant Uterine Neoplasm	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
MAP2K1 Gene Mutation	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Medulloblastoma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, Chromosome 9q Loss	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, G3/G4	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, Group 3	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, Group 4	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, Non-WNT Non-SHH, NOS	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, Non-WNT/Non-SHH	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, PTCH1 Mutation	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, SHH-activated and TP53 Mutant	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, SHH-activated and TP53 Wildtype	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma, WNT-activated	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloblastoma; Unspecified Site	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Medulloepithelioma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Melanoma (Skin)	NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	withdrawn	PHASE2	0
Melanoma Stage III	NCT05171374	pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	unknown	N/A	500
Melanoma Stage IIIb-IVM1a	NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	withdrawn	PHASE2	0
Melanoma Stage IV	NCT05171374	pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	unknown	N/A	500
Meningioma	NCT03631953	Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	recruiting	PHASE1	25
MET Exon 14 Mutation	NCT06054191	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	not yet recruiting	PHASE2	40
Metaplasia	NCT04454476	Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor	active not recruiting	PHASE1	15
Metastasis	NCT07477457	A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma	recruiting	PHASE2	45
Metastasis Skin	NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	withdrawn	PHASE2	0
Metastatic Breast Carcinoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Metastatic Cancer	NCT03714958	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type	completed	PHASE1	12
Metastatic Colon Carcinoma	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Metastatic Colorectal Adenocarcinoma	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Metastatic Colorectal Cancer	NCT03668431	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	unknown	PHASE2	25
Metastatic Colorectal Carcinoma	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Metastatic Epithelioid Hemangioendothelioma	NCT03148275	Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery	completed	PHASE2	44
Metastatic Malignant Neoplasm in the Liver	NCT02070549	Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	completed	PHASE1	46
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	NCT03299088	Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations	completed	PHASE1	15
Metastatic NRAS Melanoma	NCT03979651	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma	completed	NA	29
Metastatic Pancreatic Adenocarcinoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Metastatic Pancreatic Carcinoma	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Metastatic Prostate Carcinoma	NCT02881242	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	active not recruiting	PHASE2	14
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation	NCT03244956	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer	completed	PHASE2	40
Metastatic Rectal Carcinoma	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Metastatic Thyroid Cancer	NCT04619316	Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition	unknown	PHASE2	70
Metastatic Thyroid Gland Carcinoma	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Metastatic Uveal Melanoma	NCT05677373	Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma	withdrawn	PHASE1/PHASE2	0
Micropapillary Serous Carcinoma	NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260
Mixed Glio-neuronal Tumors	NCT05180825	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy	recruiting	PHASE2	134
Mutation	NCT06563999	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.	recruiting	PHASE2	120
Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Neoplasia	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
Neoplasm	NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550
Neoplasms by Histologic Type	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Neoplasms by Site	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Neoplasms, Colorectal	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
Neoplasms, Neuroepithelial	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Neuroblastoma. CNS	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Neuroepithelial Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Neuroepithelial Tumor, High Grade	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Neurofibroma, Plexiform	NCT03741101	Treatment of NF1-related Plexiform Neurofibroma With Trametinib	unknown	PHASE2	15
Non-Melanoma Skin Cancer (NMSC)	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Non-Small-Cell Lung Cancer	NCT02672358	Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC	withdrawn	PHASE2	0
Non-Small Cell Lung Carcinoma	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
Noonan Syndrome	NCT06555237	MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies	recruiting	PHASE2	40
NRAS Wildtype	NCT02399943	A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	completed	PHASE2	14
NSCLC Stage IV	NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	recruiting	N/A	80
Osteosarcoma	NCT07477457	A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma	recruiting	PHASE2	45
Ovarian Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Ovarian Neoplasms	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Ovarian Serous Adenocarcinoma	NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260
Pancreatic Adenocarcinoma	NCT04303403	Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma	unknown	PHASE1	48
Pancreatic Cancer for Phase II	NCT02703571	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors	terminated	PHASE1	95
Pancreatic Ductal Adenocarcinoma	NCT05440942	Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma	completed	PHASE1	28
Papillary Tumor of the Pineal Region (High-grade Only)	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8	NCT04310397	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	terminated	PHASE2	4
Pathologic Stage IIID Cutaneous Melanoma AJCC v8	NCT04310397	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	terminated	PHASE2	4
Pathologic Stage IV Cutaneous Melanoma AJCC v8	NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	terminated	PHASE2	5
Pediatric Brain Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Pineoblastoma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Pleomorphic Xanthoastrocytoma, Anaplastic	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Plexiform Neurofibroma	NCT03363217	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	active not recruiting	PHASE2	114
Precision Medicine	NCT06739395	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	recruiting	PHASE2	300
Primary Myelofibrosis	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Primary Peritoneal Serous Adenocarcinoma	NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260
Primitive Neuroectodermal Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Progesterone Receptor Negative	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
Progressive Metastatic Castrate Resistant Prostate Cancer	NCT03386071	Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib	no longer available	N/A	0
Prostate Cancer	NCT01990196	Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer	active not recruiting	PHASE2	45
Prostate Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Rare Cancers	NCT03340506	Dabrafenib and/or Trametinib Rollover Study	recruiting	PHASE4	100
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
RAS Family Gene Mutation	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Ras/MAPK Pathway Vascular Anomalies	NCT07549646	24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs	active not recruiting	PHASE2	45
Rectal Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Acute Lymphoblastic Leukemia	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Adult Acute Myeloid Leukemia	NCT01907815	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	terminated	PHASE2	24
Recurrent Adult Liver Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Recurrent Bladder Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Cervical Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Childhood Liver Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Recurrent Chronic Lymphocytic Leukemia	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Chronic Myelomonocytic Leukemia	NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21
Recurrent Colon Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Colorectal Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Esophageal Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Extrahepatic Bile Duct Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Recurrent Gallbladder Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Recurrent Gastric Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Glioma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Head and Neck Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Hematologic Malignancy	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Liver Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Low Grade Glioma	NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	recruiting	PHASE2	96
Recurrent Lung Adenocarcinoma	NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24
Recurrent Lung Cancer	NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24
Recurrent Lung Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Lymphoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Malignant Solid Neoplasm	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Malignant Uterine Corpus Neoplasm	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Medulloblastoma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Recurrent Multiple Myeloma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Myelodysplastic/Myeloproliferative Neoplasm	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Myeloproliferative Neoplasm	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Non-Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Non-Squamous Non-Small Cell Lung Carcinoma	NCT03299088	Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations	completed	PHASE1	15
Recurrent Ovarian Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Ovarian Low Grade Serous Adenocarcinoma	NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260
Recurrent Pancreatic Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Primary Peritoneal Serous Adenocarcinoma	NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260
Recurrent Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Recurrent Rectal Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Skin Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Recurrent Small Lymphocytic Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Recurrent Thyroid Cancer	NCT01723202	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	completed	PHASE2	53
Recurrent Uterine Corpus Cancer	NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26
Recurrent Uveal Melanoma	NCT01979523	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	active not recruiting	PHASE2	42
Recurrent World Health Organization (WHO) Grade II Glioma	NCT04485559	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	recruiting	PHASE1	50
Refractory Acute Lymphoblastic Leukemia	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Brain Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Refractory Chronic Lymphocytic Leukemia	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Colorectal Adenocarcinoma	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Refractory Differentiated Thyroid Gland Carcinoma	NCT06475989	Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer	recruiting	PHASE3	264
Refractory Hematologic Malignancy	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Myelodysplastic/Myeloproliferative Neoplasm	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Non-Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Primary Myelofibrosis	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Small Lymphocytic Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Refractory Thyroid Gland Carcinoma	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Refractory Tumor	NCT06456138	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	not yet recruiting	PHASE1/PHASE2	60
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer	NCT02258607	Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase	terminated	PHASE1	21
Rosacea, Erythematotelangiectatic	NCT05616923	Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea	completed	PHASE1	12
Rosette-forming Glioneurona Tumor	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Rosette-forming Glioneuronal Tumor	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
Sex Disorder	NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	recruiting	N/A	80
Skin Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Soft Tissue Sarcoma	NCT03784014	Molecular Profiling of Advanced Soft-tissue Sarcomas	completed	PHASE3	603
Solid Tumor Cancer	NCT06962254	Imatinib and Trametinib for KRAS-mutated Solid Tumor	recruiting	PHASE1	10
Solid Tumor, Adult	NCT04803318	Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors	recruiting	PHASE2	100
Solid Tumors for Phase Ib	NCT02703571	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors	terminated	PHASE1	95
Solid Tumors, KRAS Mutation; SOS1	NCT04111458	A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)	active not recruiting	PHASE1	71
Solid Tumour	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Squamous Cell Carcinoma of the Head and Neck	NCT02538627	Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib	terminated	PHASE1	5
Stage I Gastric Cancer	NCT04454476	Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor	active not recruiting	PHASE1	15
Stage II Gallbladder Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage II Pancreatic Cancer	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Stage II Pancreatic Cancer AJCC v8	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Stage IIA Pancreatic Cancer	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Stage IIA Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Stage IIB Melanoma (Locally Advanced)	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Stage IIB Pancreatic Cancer	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Stage IIB Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Stage IIC Melanoma (Locally Advanced)	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Stage IIC Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Stage III Childhood Hepatocellular Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage III Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage III Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage III Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage III Lung Non-Small Cell Cancer AJCC v7	NCT01912625	Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	terminated	PHASE1	16
Stage III Pancreatic Cancer	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Stage III Pancreatic Cancer AJCC v8	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Stage III Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIA Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIA Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIA Gallbladder Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage IIIA Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IIIA Lung Non-Small Cell Cancer AJCC v7	NCT01912625	Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	terminated	PHASE1	16
Stage IIIA Melanoma	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Stage IIIA Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Stage IIIA Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIB Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIB Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIB Gallbladder Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage IIIB Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IIIB Lung Non-Small Cell Cancer AJCC v7	NCT01912625	Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	terminated	PHASE1	16
Stage IIIB NSCLC	NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	not yet recruiting	N/A	36
Stage IIIB Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Stage IIIB Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIC Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIC Colorectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IIIC Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IIIC Rectal Cancer	NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19
Stage IIIC Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IV Breast Cancer	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
Stage IV Childhood Hepatocellular Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage IV Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IV Distal Bile Duct Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage IV Lung Cancer	NCT05435846	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	terminated	PHASE1	3
Stage IV Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IV Lung Non-Small Cell Cancer AJCC v7	NCT02642042	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	active not recruiting	PHASE2	60
Stage IV Melanoma (Limited, Resectable)	NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13
Stage IV Non-Small Cell Lung Cancer AJCC v7	NCT03299088	Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations	completed	PHASE1	15
Stage IV NSCLC	NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	not yet recruiting	N/A	36
Stage IV Pancreatic Cancer	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Stage IV Pancreatic Cancer AJCC v8	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Stage IV Prostate Cancer	NCT02881242	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	active not recruiting	PHASE2	14
Stage IV Prostate Cancer AJCC v8	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Stage IV Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IV Thyroid Gland Follicular Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IV Thyroid Gland Papillary Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IV Uveal Melanoma AJCC v7	NCT01979523	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	active not recruiting	PHASE2	42
Stage IVA Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IVA Gallbladder Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage IVA Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IVA Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IVB Colon Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IVB Gallbladder Cancer	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Stage IVB Lung Cancer AJCC v8	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Stage IVB Rectal Cancer AJCC v7	NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26
Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7	NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34
Thyroid Cancer, Follicular	NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19
Thyroid Carcinoma, Anaplastic	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Thyroid Carcinoma, Papillary	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Thyroid Gland Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Thyroid Gland Squamous Cell Carcinoma	NCT04675710	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	active not recruiting	PHASE2	30
Triple-Negative Breast Carcinoma	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
Tumor Skin	NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	withdrawn	PHASE2	0
Unresectable Epithelioid Hemangioendothelioma	NCT03148275	Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery	completed	PHASE2	44
Unresectable Extrahepatic Bile Duct Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Unresectable Lung Non-Small Cell Carcinoma	NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37
Unresectable Pancreatic Adenocarcinoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Unresectable Pancreatic Carcinoma	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25
Unresectable Uveal Melanoma	NCT05677373	Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma	withdrawn	PHASE1/PHASE2	0
Untreated Adult Acute Myeloid Leukemia	NCT01907815	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	terminated	PHASE2	24
Vascular Anomaly	NCT07549646	24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs	active not recruiting	PHASE2	45
Venous Malformation	NCT04258046	Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation	completed	PHASE2	25
WHO Grade 3 Glioma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
WHO Grade 4 Glioma	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
Rare Malignant Neoplasm	NCT06119789	Precision Cancer Therapy in Rare Cancers	recruiting	PHASE2	96
Acute Lymphoblastic Leukemia, in Relapse	NCT05658640	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	recruiting	PHASE1/PHASE2	26
Acute Myeloid Leukemia	NCT02016729	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	completed	PHASE1	36
Adenocarcinoma	NCT02428270	A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	completed	PHASE2	16
Adjuvant	NCT04544202	Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection	no longer available	N/A	0
Adult Cholangiocarcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Advanced Adult Hepatocellular Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Advanced BRAF Mutant Melanoma	NCT02257424	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma	completed	PHASE1/PHASE2	50
Advanced Lung Cancer	NCT06456138	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	not yet recruiting	PHASE1/PHASE2	60
Advanced Malignancies	NCT05048134	A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies	terminated	PHASE1	13
Advanced Melanoma	NCT03501368	Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma	completed	PHASE1	27
Advanced or Metastatic NRAS-mutant Melanoma	NCT06346067	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)	active not recruiting	PHASE3	78
Advanced or Metastatic Solid Tumors	NCT05907304	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations	active not recruiting	PHASE1	86
Advanced Solid Tumors Harboring the KRAS G12C Mutation	NCT07468071	Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments	recruiting	PHASE1/PHASE2	40
Advanced Thyroid Cancer Patients Who Received Target Therapy	NCT06195228	A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer	recruiting	PHASE4	800
Advanced Uveal Melanoma	NCT05677373	Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma	withdrawn	PHASE1/PHASE2	0
Amyotrophic Lateral Sclerosis	NCT04326283	Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)	terminated	PHASE1/PHASE2	23
Anaplastic Astrocytoma, Not Otherwise Specified	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58
Anaplastic Ependymoma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Anaplastic Meningioma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Anatomic Stage IV Breast Cancer AJCC v8	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Anemia	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Ann Arbor Stage III Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Ann Arbor Stage III Non-Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Ann Arbor Stage IV Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Ann Arbor Stage IV Non-Hodgkin Lymphoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Arterial Disease	NCT04258046	Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation	completed	PHASE2	25
Arteriovenous Malformations	NCT06098872	Pilot Study on Trametinib for Surgical Unruptured AVMs	withdrawn	PHASE2	0
ATC	NCT05668585	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	completed	PHASE1	89
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Atypical Teratoid/Rhabdoid Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
BCLC Stage C Adult Hepatocellular Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
BCLC Stage D Adult Hepatocellular Carcinoma	NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53
Bile Duct Cancer	NCT04566133	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	terminated	PHASE2	2
Biliary Cancer	NCT04566133	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	terminated	PHASE2	2
Biliary Tract Neoplasms	NCT04566133	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	terminated	PHASE2	2
Bladder Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
Borderline Ovarian Serous Tumor	NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260
BRAF Mutant Melanoma	NCT01726738	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	completed	PHASE2	17
BRAF Mutation-Related Tumors	NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	PHASE2	16
BRAF NP_004324.2:p.V600E	NCT03975231	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	recruiting	PHASE1	6
BRAF V600 Colorectal Cancer	NCT04294160	A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer	terminated	PHASE1	122
BRAF V600E	NCT03543306	Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation	unknown	PHASE2	27
BRAF V600E Mutation Positive	NCT06653517	Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma	recruiting	PHASE2	12
BRAF Wildtype	NCT02399943	A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	completed	PHASE2	14
BRAFV600E Melanoma Patients	NCT01721603	Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets	terminated	PHASE2	2
Brain Cancer	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Brain Metastases	NCT02974803	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	terminated	PHASE2	6
Brain Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Breast Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Bronchial Neoplasms	NCT03516214	EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations	completed	PHASE1	18
Carcinoma, Non-Small Cell-Lung	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Carcinoma, Non-Small Cell Lung	NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74
Cardiomegaly	NCT06555237	MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies	recruiting	PHASE2	40
Castration-Resistant Prostate Carcinoma	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
CBL Syndrome	NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	recruiting	PHASE1/PHASE2	58
Central Nervous System Glioma	NCT03363217	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	active not recruiting	PHASE2	114
Central Nervous System Neoplasms	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Cerebellar Iponeurocytoma	NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151
Cerebellar Liponeurocytoma	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165
Cervical Cancer	NCT01958112	GSK1120212+GSK2141795 for Cervical Cancer	terminated	PHASE2	14
Cervical Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Child	NCT03741101	Treatment of NF1-related Plexiform Neurofibroma With Trametinib	unknown	PHASE2	15
Choroid Plexus Carcinoma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2
CNS Embryonal Tumor With Rhabdoid Features	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
CNS Tumor	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Colon Cancer	NCT03428126	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	completed	PHASE2	29
Colon Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Colorectal Cancer for Phase II	NCT02703571	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors	terminated	PHASE1	95
Colorectal Neoplasm	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread	completed	PHASE1/PHASE2	325
Craniopharyngioma	NCT05525273	Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma	recruiting	PHASE2	25
CRC	NCT05668585	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	completed	PHASE1	89
Differentiated Thyroid Cancer (DTC)	NCT04940052	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer	active not recruiting	PHASE3	153
EGFR-mutant Non-small Cell Lung Cancer	NCT03333343	Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	active not recruiting	PHASE1	105
EGFR Gene Amplification	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
EGFR Gene Mutation	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
EGFR NP_005219.2:p.S492R	NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59
Embryonal Tumor of CNS	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Embryonal Tumor With Multilayered Rosettes (ETMR)	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Embryonal Tumor, NOS	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Endometrial Adenocarcinoma	NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26
Endometrial Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Endometrial Clear Cell Adenocarcinoma	NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26
Endometrial Mixed Cell Adenocarcinoma	NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26
Endometrial Serous Adenocarcinoma	NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26
Endometrial Undifferentiated Carcinoma	NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26
Ependymoma	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Ependymoma, NOS, WHO Grade II	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Ependymoma, NOS, WHO Grade III	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Ependymoma, Recurrent	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Ependymoma, RELA Fusion Positive	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
ERBB2 Gene Amplification	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
ERBB2 Gene Mutation	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
ERBB3 Gene Mutation	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
ERBB4 Gene Mutation	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93
Erectile Dysfunction	NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	recruiting	N/A	80
Esophageal Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Estrogen Receptor Negative	NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37
Exocrine Pancreas Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Fertility	NCT07092670	MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.	recruiting	N/A	270
Ganglioneuroblastoma of Central Nervous System	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Gastric Cancer	NCT04454476	Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor	active not recruiting	PHASE1	15
Gastric Carcinoma	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452
Gastrointestinal Cancer	NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30
Gastrointestinal Stromal Tumors	NCT02342600	SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)	withdrawn	PHASE2	0
Glioblastoma, IDH-mutant	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Glioblastoma, IDH-wildtype	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Glioma, Diffuse Midline, H3K27M-mutant	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Glioma, High Grade	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Glioma, Malignant	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Glioma, Recurrent High Grade	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Glioma, Recurrent Malignant	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68
Grade 1 Glioma	NCT05180825	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy	recruiting	PHASE2	134

All Trametinib Clinical Trials (243)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07468071	Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments	recruiting	PHASE1/PHASE2	40	Novartis Pharmaceuticals
NCT07477457	A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma	recruiting	PHASE2	45	Memorial Sloan Kettering Cancer Center
NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	not yet recruiting	PHASE2/PHASE3	30	Cancer Research UK
NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	not yet recruiting	PHASE1/PHASE2	221	Xynomic Pharmaceuticals, Inc.
NCT07419932	Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer	recruiting	N/A	120	Fujian Medical University
NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	recruiting	PHASE2	96	University of California, San Francisco
NCT07549646	24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs	active not recruiting	PHASE2	45	Children's Hospital of Philadelphia
NCT07092670	MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.	recruiting	N/A	270	Intergruppo Melanoma Italiano
NCT07072403	Trametinib Treatment for Complicated Vascular Anomalies	active not recruiting	PHASE1/PHASE2	20	West China Hospital
NCT07010393	Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study	not yet recruiting	PHASE4	335	Fujian Medical University
NCT07022834	Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children	recruiting	PHASE2	20	West China Second University Hospital
NCT06962254	Imatinib and Trametinib for KRAS-mutated Solid Tumor	recruiting	PHASE1	10	China Medical University Hospital
NCT06712875	MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas	recruiting	PHASE1/PHASE2	27	Ann & Robert H Lurie Children's Hospital of Chicago
NCT06119789	Precision Cancer Therapy in Rare Cancers	recruiting	PHASE2	96	Oslo University Hospital
NCT06819605	Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma	not yet recruiting	PHASE2/PHASE3	46	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT06967155	A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer	active not recruiting	PHASE2	23	Blokhin's Russian Cancer Research Center
NCT06804824	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors	recruiting	PHASE1	220	Vividion Therapeutics, Inc.
NCT06739395	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	recruiting	PHASE2	300	Tianjin Medical University Second Hospital
NCT06563999	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.	recruiting	PHASE2	120	Sun Yat-sen University
NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	recruiting	PHASE1/PHASE2	58	Therapeutic Advances in Childhood Leukemia Consortium
NCT06475989	Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer	recruiting	PHASE3	264	ECOG-ACRIN Cancer Research Group
NCT06532149	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	recruiting	N/A	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06555237	MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies	recruiting	PHASE2	40	Medical University of Warsaw
NCT06456138	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	not yet recruiting	PHASE1/PHASE2	60	Shanghai Chest Hospital
NCT06582745	Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib	recruiting	PHASE2	75	Cook Children's Health Care System
NCT06346067	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)	active not recruiting	PHASE3	78	Erasca, Inc.
NCT06362694	Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	recruiting	PHASE2	10	Saint Petersburg State University, Russia
NCT06054191	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	not yet recruiting	PHASE2	40	Sun Yat-sen University
NCT06098872	Pilot Study on Trametinib for Surgical Unruptured AVMs	withdrawn	PHASE2	0	University Health Network, Toronto
NCT05658640	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	recruiting	PHASE1/PHASE2	26	Princess Maxima Center for Pediatric Oncology
NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	not yet recruiting	N/A	36	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NCT05525273	Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma	recruiting	PHASE2	25	Eva Marie Erfurth, MD, PhD
NCT05874414	Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma	recruiting	PHASE1/PHASE2	74	Genfit
NCT05907304	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations	active not recruiting	PHASE1	86	Erasca, Inc.
NCT05876806	Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations	unknown	PHASE2	30	Se Jun Park
NCT05518110	PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer	terminated	PHASE2	20	Cancer Trials Ireland
NCT05440942	Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma	completed	PHASE1	28	Peter Hosein, MD
NCT05677373	Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma	withdrawn	PHASE1/PHASE2	0	Alliance for Clinical Trials in Oncology
NCT06653517	Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma	recruiting	PHASE2	12	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT06079333	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)	recruiting	PHASE2	20	Leiden University Medical Center
NCT05668585	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	completed	PHASE1	89	C4 Therapeutics, Inc.
NCT04454476	Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor	active not recruiting	PHASE1	15	Vanderbilt-Ingram Cancer Center
NCT05358249	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	active not recruiting	PHASE1/PHASE2	74	Novartis Pharmaceuticals
NCT05372354	A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma	recruiting	PHASE1/PHASE2	260	Bristol-Myers Squibb
NCT05435846	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	terminated	PHASE1	3	Collin Blakely
NCT05182931	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	unknown	PHASE2	80	Olivia Newton-John Cancer Research Institute
NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	recruiting	PHASE1	30	Rina Plattner
NCT05180825	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy	recruiting	PHASE2	134	University Hospital, Strasbourg, France
NCT04566133	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	terminated	PHASE2	2	National Cancer Institute (NCI)
NCT05260684	Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US	completed	N/A	716	Pfizer
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	recruiting	PHASE2	250	Helsinki University Central Hospital
NCT04961619	Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.	completed	N/A	39	Novartis Pharmaceuticals
NCT02645149	Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma	completed	PHASE2	216	Melanoma Institute Australia
NCT04940052	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer	active not recruiting	PHASE3	153	Novartis Pharmaceuticals
NCT05616923	Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea	completed	PHASE1	12	Albany Research Institute, Inc.
NCT05048134	A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies	terminated	PHASE1	13	Jiangsu HengRui Medicine Co., Ltd.
NCT04547946	Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)	completed	N/A	3	Novartis Pharmaceuticals
NCT05714371	Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma	completed	N/A	618	Novartis Pharmaceuticals
NCT05171374	pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	unknown	N/A	500	MelanomaPRO, Russia
NCT05071183	A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors	terminated	PHASE1/PHASE2	9	Turning Point Therapeutics, Inc.
NCT04801966	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	terminated	NA	3	Peter MacCallum Cancer Centre, Australia
NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	PHASE1/PHASE2	16	National Cancer Institute (NCI)
NCT04967079	Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients	completed	PHASE1	33	Shanghai Chest Hospital
NCT04675710	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	active not recruiting	PHASE2	30	M.D. Anderson Cancer Center
NCT04892017	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors	terminated	PHASE1	91	Deciphera Pharmaceuticals, LLC
NCT04527549	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	terminated	PHASE2	5	ECOG-ACRIN Cancer Research Group
NCT06482086	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer	recruiting	PHASE2	75	West China Hospital
NCT04943224	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients	recruiting	PHASE2	12	Anna Raciborska
NCT05299580	"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"	withdrawn	PHASE2	0	Fondazione Melanoma Onlus
NCT04739566	Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer	withdrawn	PHASE2	0	Saint Petersburg State University, Russia
NCT04803318	Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors	recruiting	PHASE2	100	Second Affiliated Hospital of Guangzhou Medical University
NCT04666272	Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection	active not recruiting	N/A	78	Novartis Pharmaceuticals
NCT04554680	Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy	unknown	PHASE2	5	National University Hospital, Singapore
NCT04485559	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	recruiting	PHASE1	50	University of California, San Francisco
NCT04258046	Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation	completed	PHASE2	25	Stanford University
NCT04417621	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	active not recruiting	PHASE2	134	Novartis Pharmaceuticals
NCT03975231	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	recruiting	PHASE1	6	City of Hope Medical Center
NCT04544111	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	active not recruiting	PHASE2	19	Memorial Sloan Kettering Cancer Center
NCT04452877	A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC	completed	PHASE2	40	Novartis Pharmaceuticals
NCT04294160	A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer	terminated	PHASE1	122	Novartis Pharmaceuticals
NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	completed	PHASE2	21	M.D. Anderson Cancer Center
NCT05611229	Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden	completed	N/A	1,975	Novartis Pharmaceuticals
NCT04326283	Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)	terminated	PHASE1/PHASE2	23	Genuv Inc.
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	terminated	PHASE1	2	OHSU Knight Cancer Institute
NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	PHASE2	58	National Cancer Institute (NCI)
NCT04310397	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	terminated	PHASE2	4	M.D. Anderson Cancer Center
NCT04116541	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.	recruiting	PHASE2	455	Centre Leon Berard
NCT04238624	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	active not recruiting	PHASE2	16	Memorial Sloan Kettering Cancer Center
NCT04201457	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	active not recruiting	PHASE1/PHASE2	57	Pediatric Brain Tumor Consortium
NCT06195228	A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer	recruiting	PHASE4	800	Fudan University
NCT04185883	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	active not recruiting	PHASE1	610	Amgen
NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	PHASE4	165	Novartis Pharmaceuticals
NCT04111458	A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)	active not recruiting	PHASE1	71	Boehringer Ingelheim
NCT03784014	Molecular Profiling of Advanced Soft-tissue Sarcomas	completed	PHASE3	603	Institut National de la Santé Et de la Recherche Médicale, France
NCT03979651	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma	completed	NA	29	Hospices Civils de Lyon
NCT03631953	Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	recruiting	PHASE1	25	Assistance Publique Hopitaux De Marseille
NCT03899155	Pan Tumor Rollover Study	recruiting	PHASE2	1,500	Bristol-Myers Squibb
NCT03944356	BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	completed	N/A	232	EuMelaReg gGmbH
NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	withdrawn	PHASE2	0	TriHealth Inc.
NCT03741101	Treatment of NF1-related Plexiform Neurofibroma With Trametinib	unknown	PHASE2	15	Region Skane
NCT03272464	INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.	terminated	PHASE1	1	Massachusetts General Hospital
NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	terminated	PHASE1	25	University of Utah
NCT04059224	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma	completed	PHASE2	45	Universitair Ziekenhuis Brussel
NCT03794297	Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations	withdrawn	PHASE2	0	National Cancer Institute (NCI)
NCT03714958	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type	completed	PHASE1	12	Centre Leon Berard
NCT03668431	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	unknown	PHASE2	25	Massachusetts General Hospital
NCT03704688	Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer	completed	PHASE1/PHASE2	12	Memorial Sloan Kettering Cancer Center
NCT03455764	MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	completed	PHASE1/PHASE2	6	Dana-Farber Cancer Institute
NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	active not recruiting	PHASE2	10	National Cancer Institute (NCI)
NCT02672358	Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC	withdrawn	PHASE2	0	Novartis Pharmaceuticals
NCT03551626	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes	completed	PHASE3	552	Novartis Pharmaceuticals
NCT03363217	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	active not recruiting	PHASE2	114	St. Justine's Hospital
NCT04303403	Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma	unknown	PHASE1	48	National Cancer Centre, Singapore
NCT03580382	Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma	terminated	PHASE1/PHASE2	3	NYU Langone Health
NCT03543306	Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation	unknown	PHASE2	27	Asan Medical Center
NCT03501368	Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma	completed	PHASE1	27	H. Lee Moffitt Cancer Center and Research Institute
NCT03299088	Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations	completed	PHASE1	15	Jonathan Riess
NCT03563729	Melanoma Metastasized to the Brain and Steroids	recruiting	PHASE2	80	Inge Marie Svane
NCT03516214	EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations	completed	PHASE1	18	University of Cologne
NCT03317119	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	completed	PHASE1	26	City of Hope Medical Center
NCT03428126	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	completed	PHASE2	29	M.D. Anderson Cancer Center
NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	completed	PHASE1	68	St. Jude Children's Research Hospital
NCT03232892	Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer	terminated	PHASE2	1	University of California, San Francisco
NCT02974803	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	terminated	PHASE2	6	Canadian Cancer Trials Group
NCT04619316	Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition	unknown	PHASE2	70	University Hospital, Essen
NCT03225664	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	active not recruiting	PHASE1/PHASE2	37	M.D. Anderson Cancer Center
NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread	completed	PHASE1/PHASE2	325	Bristol-Myers Squibb
NCT02881242	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	active not recruiting	PHASE2	14	Jonsson Comprehensive Cancer Center
NCT03333343	Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	active not recruiting	PHASE1	105	Novartis Pharmaceuticals
NCT03754179	Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma	unknown	PHASE1/PHASE2	63	Universitair Ziekenhuis Brussel
NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	active not recruiting	PHASE2	59	M.D. Anderson Cancer Center
NCT03340506	Dabrafenib and/or Trametinib Rollover Study	recruiting	PHASE4	100	Novartis Pharmaceuticals
NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	PHASE2	151	Novartis Pharmaceuticals
NCT03244956	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer	completed	PHASE2	40	Gustave Roussy, Cancer Campus, Grand Paris
NCT03149029	Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma	active not recruiting	PHASE2	16	Massachusetts General Hospital
NCT03266159	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors	withdrawn	PHASE2	0	GlaxoSmithKline
NCT02858921	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	unknown	PHASE2	60	Melanoma Institute Australia
NCT03352947	Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma	completed	PHASE2	79	Cambridge University Hospitals NHS Foundation Trust
NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	active not recruiting	PHASE1	93	M.D. Anderson Cancer Center
NCT03087448	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	terminated	PHASE1	9	University of California, San Francisco
NCT02367859	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	completed	PHASE2	1	Stanford University
NCT03088176	Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma	unknown	PHASE1	4	West Cancer Center
NCT03091257	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	active not recruiting	PHASE1	30	Massachusetts General Hospital
NCT03148275	Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery	completed	PHASE2	44	National Cancer Institute (NCI)
NCT02447939	Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma	withdrawn	PHASE1	0	GlaxoSmithKline
NCT02939846	Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours	withdrawn	PHASE1	0	GlaxoSmithKline
NCT03085056	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	active not recruiting	EARLY_PHASE1	13	Memorial Sloan Kettering Cancer Center
NCT03076164	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	completed	PHASE1/PHASE2	24	Memorial Sloan Kettering Cancer Center
NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	terminated	PHASE1	241	Novartis Pharmaceuticals
NCT02967692	A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma	terminated	PHASE3	568	Novartis Pharmaceuticals
NCT02872259	BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma	completed	PHASE1/PHASE2	74	Haukeland University Hospital
NCT02342600	SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)	withdrawn	PHASE2	0	Sarcoma Alliance for Research through Collaboration
NCT03026517	Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma	completed	PHASE1	18	Memorial Sloan Kettering Cancer Center
NCT02910700	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	active not recruiting	PHASE2	52	M.D. Anderson Cancer Center
NCT02915666	A Clinical Trial of Patients With Melanoma	withdrawn	PHASE1	0	University of Texas Southwestern Medical Center
NCT02705963	A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors	completed	PHASE1	19	Novartis Pharmaceuticals
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	recruiting	PHASE2	1,550	The Netherlands Cancer Institute
NCT02642042	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	active not recruiting	PHASE2	60	National Cancer Institute (NCI)
NCT02703571	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors	terminated	PHASE1	95	Novartis Pharmaceuticals
NCT02428270	A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	completed	PHASE2	16	University Health Network, Toronto
NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	recruiting	PHASE2	4,200	American Society of Clinical Oncology
NCT02292732	A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors	withdrawn	PHASE1	0	GlaxoSmithKline
NCT04439318	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	active not recruiting	PHASE2	50	National Cancer Institute (NCI)
NCT04439357	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	active not recruiting	PHASE2	4	National Cancer Institute (NCI)
NCT02625337	Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients	unknown	PHASE2	32	The Netherlands Cancer Institute
NCT04439292	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	active not recruiting	PHASE2	44	National Cancer Institute (NCI)
NCT02300935	Study of Trametinib and Nab-paclitaxel in Patients With Melanoma	withdrawn	PHASE1	0	SCRI Development Innovations, LLC
NCT02410863	Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma	terminated	PHASE2	10	Prof. Dr. med. Dirk Schadendorf
NCT02580708	Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer	terminated	PHASE1/PHASE2	7	Clovis Oncology, Inc.
NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	PHASE3	267	National Cancer Institute (NCI)
NCT02538627	Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib	terminated	PHASE1	5	Merrimack Pharmaceuticals
NCT02357732	Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib	withdrawn	PHASE1	0	University of Pittsburgh
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	PHASE2	6,452	National Cancer Institute (NCI)
NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	PHASE2	35	National Cancer Institute (NCI)
NCT02399943	A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	completed	PHASE2	14	University Health Network, Toronto
NCT02392871	Radiotherapy & Combi in Metastatic Melanoma	completed	PHASE1/PHASE2	10	Melanoma and Skin Cancer Trials Limited
NCT02140840	UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib	withdrawn	PHASE2	0	University of Arkansas
NCT02258607	Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase	terminated	PHASE1	21	Sierra Oncology LLC - a GSK company
NCT02439411	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain	completed	N/A	135	Grupo Español Multidisciplinar de Melanoma
NCT02292173	Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer	completed	PHASE1	17	H. Lee Moffitt Cancer Center and Research Institute
NCT02296112	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	completed	PHASE2	9	Vanderbilt-Ingram Cancer Center
NCT02124772	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	completed	PHASE1/PHASE2	139	Novartis Pharmaceuticals
NCT02110355	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	completed	PHASE1	31	Kartos Therapeutics, Inc.
NCT02281760	Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease	completed	PHASE2	9	National Human Genome Research Institute (NHGRI)
NCT02296996	Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients	completed	PHASE2	25	Universitair Ziekenhuis Brussel
NCT02257424	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma	completed	PHASE1/PHASE2	50	Abramson Cancer Center at Penn Medicine
NCT02231775	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	active not recruiting	PHASE2	58	M.D. Anderson Cancer Center
NCT02230553	Lapatinib Plus Trametinib in KRAS Mutant NSCLC	completed	PHASE1/PHASE2	35	The Netherlands Cancer Institute
NCT01972347	Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma	active not recruiting	PHASE2	35	Melanoma Institute Australia
NCT02143050	Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients	withdrawn	PHASE1/PHASE2	0	University of Louisville
NCT01990196	Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer	active not recruiting	PHASE2	45	Jonsson Comprehensive Cancer Center
NCT02196181	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread	active not recruiting	PHASE2	280	National Cancer Institute (NCI)
NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	PHASE2	34	National Cancer Institute (NCI)
NCT02138292	A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma	completed	PHASE1	27	University of Texas Southwestern Medical Center
NCT02097225	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	22	National Cancer Institute (NCI)
NCT02130466	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	completed	PHASE1/PHASE2	184	Merck Sharp & Dohme LLC
NCT02015117	Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases	active not recruiting	PHASE1	10	National Cancer Institute (NCI)
NCT02065063	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	completed	PHASE1	28	GlaxoSmithKline
NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	completed	PHASE2/PHASE3	260	National Cancer Institute (NCI)
NCT01978236	Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites	terminated	PHASE2	6	GlaxoSmithKline
NCT02016729	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	completed	PHASE1	36	Kartos Therapeutics, Inc.
NCT02079740	Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	active not recruiting	PHASE1/PHASE2	96	National Cancer Institute (NCI)
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	PHASE1/PHASE2	75	National Cancer Institute (NCI)
NCT02083354	Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma	completed	PHASE2	77	Novartis Pharmaceuticals
NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	completed	PHASE2	206	Novartis Pharmaceuticals
NCT02070549	Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	completed	PHASE1	46	National Cancer Institute (NCI)
NCT02042443	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	completed	PHASE2	53	National Cancer Institute (NCI)
NCT02039947	Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain	completed	PHASE2	127	Novartis Pharmaceuticals
NCT01827384	MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations	completed	PHASE2	208	National Cancer Institute (NCI)
NCT02027961	Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone	completed	PHASE1	68	MedImmune LLC
NCT01979523	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	active not recruiting	PHASE2	42	National Cancer Institute (NCI)
NCT01938443	A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors	completed	PHASE1	34	GlaxoSmithKline
NCT02314143	Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib	terminated	PHASE2	48	GlaxoSmithKline
NCT01958112	GSK1120212+GSK2141795 for Cervical Cancer	terminated	PHASE2	14	Dana-Farber Cancer Institute
NCT01907815	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	terminated	PHASE2	24	National Cancer Institute (NCI)
NCT01938456	Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer	withdrawn	PHASE1	0	GlaxoSmithKline
NCT01989598	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma	completed	PHASE2	25	National Cancer Institute (NCI)
NCT01912625	Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	terminated	PHASE1	16	National Cancer Institute (NCI)
NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	PHASE1/PHASE2	27	National Cancer Institute (NCI)
NCT01964924	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	completed	PHASE2	37	National Cancer Institute (NCI)
NCT01935973	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	PHASE1	26	National Cancer Institute (NCI)
NCT01943864	A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers	completed	PHASE2	20	GlaxoSmithKline
NCT01941927	Trametinib With GSK2141795 in BRAF Wild-type Melanoma	completed	PHASE2	20	Adil Daud
NCT01940809	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	terminated	PHASE1	15	National Cancer Institute (NCI)
NCT01928940	Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)	completed	PHASE2	12	GlaxoSmithKline
NCT01721603	Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets	terminated	PHASE2	2	University of California, San Francisco
NCT01726738	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	completed	PHASE2	17	UNC Lineberger Comprehensive Cancer Center
NCT01767454	Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma	completed	PHASE1	38	GlaxoSmithKline
NCT01701037	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	terminated	PHASE2	13	Vanderbilt-Ingram Cancer Center
NCT01682083	Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).	completed	PHASE3	870	Novartis Pharmaceuticals
NCT01750918	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	completed	PHASE1/PHASE2	166	Novartis Pharmaceuticals
NCT01740648	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	completed	PHASE1	19	Ohio State University Comprehensive Cancer Center
NCT01723202	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	completed	PHASE2	53	Bhavana Konda
NCT01647659	Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation	completed	PHASE1	18	GlaxoSmithKline
NCT01597908	Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma	completed	PHASE3	704	Novartis Pharmaceuticals
NCT01584648	A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma	completed	PHASE3	423	Novartis Pharmaceuticals
NCT01336634	Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.	completed	PHASE2	177	Novartis Pharmaceuticals
NCT01192165	Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel	completed	PHASE1	169	GlaxoSmithKline
NCT01287546	A Study of LY2875358 in Participants With Advanced Cancer	completed	PHASE1	117	Eli Lilly and Company
NCT03386071	Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib	no longer available	N/A	0	Jonsson Comprehensive Cancer Center
NCT04544202	Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection	no longer available	N/A	0	Novartis Pharmaceuticals
NCT04489433	Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma	no longer available	N/A	0	Novartis Pharmaceuticals
NCT02416232	Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma	no longer available	N/A	0	GlaxoSmithKline

Where to Participate: All Trametinib Trial Sites in the U.S. (519 sites across 45 states)

Every actively recruiting Trametinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	UAB Comprehensive Cancer Center	Birmingham35249	NCT05372354	Map
AL	University of Alabama at Birmingham	Birmingham35233	NCT07110246	Map
AL	University of Alabama at Birmingham Comprehensive Cancer Center	Birmingham35294	NCT02693535	Map
AL	University of Alabama at Birmingham, Children's of Alabama	Birmingham35233	NCT04485559	Map
AK	Alaska Breast Care and Surgery LLC	Anchorage99508	NCT06475989	Map
AK	Alaska Oncology and Hematology LLC	Anchorage99508	NCT06475989	Map
AK	Alaska Women's Cancer Care	Anchorage99508	NCT06475989	Map
AK	Anchorage Associates in Radiation Medicine	Anchorage98508	NCT06475989	Map
AK	Katmai Oncology Group	Anchorage99508	NCT06475989	Map
AK	Providence Alaska Medical Center	Anchorage99508	NCT06475989	Map
AZ	Cancer Treatment Centers of America-Phoenix	Phoenix85338	NCT02693535	Map
AZ	Phoenix Children's Hospital	Phoenix85016	NCT05849662	Map
AZ	Honor Health Research Institute	Scottsdale85258	NCT03340506	Map
AR	Mercy Hospital Fort Smith	Fort Smith72903	NCT06475989	Map
AR	CARTI Cancer Center	Little Rock72205	NCT06475989	Map
CA	Sutter Auburn	Auburn95602	NCT02693535	Map
CA	Sutter Alta Bates	Berkeley94705	NCT02693535	Map
CA	Providence Saint Joseph Medical Center/Disney Family Cancer Center	Burbank91505	NCT06475989	Map
CA	City of Hope Medical Center	Duarte91010	NCT03975231	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT06475989	Map
CA	Children's Hospital Los Angeles	Los Angeles90027	NCT04485559	Map
CA	Children's Hospital Los Angeles	Los Angeles900027	NCT05849662	Map
CA	LACN Aneheim Flagship Office	Los Angeles92805	NCT05874414	Map
CA	The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate	Los Angeles90025	NCT02693535	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT05874414	Map
CA	Providence Queen of The Valley	Napa94558	NCT06475989	Map
CA	Kaiser Permanente - Oakland Medical Center	Oakland94611	NCT02693535	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT06475989	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT06475989	Map
CA	Sutter Palo Alto Medical Foundation: Palo Alto	Palo Alto94301	NCT02693535	Map
CA	Kaiser Permanente - Roseville Medical Center	Roseville95661	NCT02693535	Map
CA	Sutter Roseville	Roseville95661	NCT02693535	Map
CA	Kaiser Permanente - Sacramento Medical Center	Sacramento95814	NCT02693535	Map
CA	Sutter Sacramento	Sacramento95816	NCT02693535	Map
CA	University of California, San Diego Rady Children's Hospital	San Diego92123	NCT04485559	Map
CA	California Pacific Medical Center Research Institute	San Francisco94115	NCT02693535	Map
CA	Kaiser Permanente - San Francisco Medical Center	San Francisco94115	NCT02693535	Map
CA	Kaiser Permanente - South San Francisco Medical Center	San Francisco94080	NCT02693535	Map
CA	Sutter Cancer Research Consortium	San Francisco94115	NCT02693535	Map
CA	University of California San Francisco	San Francisco94158	NCT05849662	Map
CA	University of California, San Francisco	San Francisco94143	NCT04485559	Map
CA	University of California, San Francisco	San Francisco94143	NCT07110246	Map
CA	Kaiser Permanente - San Jose Medical Center	San Jose95119	NCT02693535	Map
CA	Kaiser Permanente - San Leandro Medical Center	San Leandro94577	NCT02693535	Map
CA	Sutter Sansum Clinic	Santa Barbara93105	NCT02693535	Map
CA	Kaiser Permanente - Santa Clara Medical Center	Santa Clara95051	NCT02693535	Map
CA	Sutter Palo Alto Medical Foundation: Fremont	Santa Cruz994538	NCT02693535	Map
CA	Sutter Palo Alto Medical Foundation: Santa Cruz	Santa Cruz95065	NCT02693535	Map
CA	Providence Medical Foundation - Santa Rosa	Santa Rosa95403	NCT06475989	Map
CA	Providence Santa Rosa Memorial Hospital	Santa Rosa95405	NCT06475989	Map
CA	Sutter Palo Alto Medical Foundation: Sunnyvale	Sunnyvale94086	NCT02693535	Map
CA	Kaiser Permanente - Vallejo Medical Center	Vallejo94589	NCT02693535	Map
CA	Kaiser Permanente - Walnut Creek Medical Center	Walnut Creek94596	NCT02693535	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06475989	Map
CO	Children's Hospital of Colorado	Denver80045	NCT05849662	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT06475989	Map
CT	Saint Vincent's Medical Center (SVMC)	Bridgeport06606	NCT02693535	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06475989	Map
CT	Hartford Hospital	Hartford06102	NCT02693535	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT06475989	Map
CT	Midstate Medical Center (MSMC)	Meriden06451	NCT02693535	Map
CT	The Hospital of Central Connecticut (HOCC) Cancer Center	New Britain06053	NCT02693535	Map
CT	Smilow Cancer Center/Yale-New Haven Hospital	New Haven06510	NCT06475989	Map
CT	Yale University	New Haven06520	NCT06475989	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06475989	Map
CT	William W. Backus Hospital	Norwich06360	NCT02693535	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT06475989	Map
CT	Charlotte Hungerford	Torrington06790	NCT02693535	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06475989	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06475989	Map
CT	Windham Hospital (WH)	Willimantic06226	NCT02693535	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT04485559	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT05849662	Map
FL	University of Miami/Sylvester Cancer Institute - Aventura	Aventura33180	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Lennar	Coral Gables33146	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Deerfield Beach	Deerfield Beach33442	NCT02693535	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT02693535	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT06475989	Map
FL	University of Florida	Gainesville32610-0265	NCT04485559	Map
FL	University of Florida Health	Gainesville32610	NCT02693535	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06475989	Map
FL	University of Miami	Miami33136	NCT05849662	Map
FL	University of Miami Sylvester Comprehensive Cancer Center	Miami33136	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Alex's Place	Miami33136	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building	Miami33136	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Kendall	Miami33176	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Sole Mia	Miami33181	NCT02693535	Map
FL	Orlando Health	Orlando32806	NCT05874414	Map
FL	University of Miami/Sylvester Cancer Institute - Plantation	Plantation33324	NCT02693535	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05874414	Map
GA	Cancer Treatment Centers of America - Atlanta	Atlanta30265	NCT02693535	Map
GA	Children's Hospital of Atlanta	Atlanta30322	NCT05849662	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06475989	Map
GA	Emory University Winship Cancer Institute	Atlanta30322	NCT02693535	Map
GA	Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion	Savannah31405	NCT02693535	Map
GA	Lewis Cancer & Research Pavilion	Savannah31405	NCT02693535	Map
GA	Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute	Savannah31405	NCT02693535	Map
GA	Summit Cancer Care	Savannah31405	NCT02693535	Map
HI	The Queen's Medical Center - West Oahu	‘Ewa Beach96706	NCT02693535	Map
HI	The Queen's Medical Center - Kuakini	Honolulu96817	NCT02693535	Map
HI	The Queen's Medical Center - POB I	Honolulu96813	NCT02693535	Map
HI	The Queen's Medical Center - Punchbowl	Honolulu96813	NCT02693535	Map
ID	Saint Alphonsus Cancer Care Center-Boise	Boise83706	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT06475989	Map
ID	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell83605	NCT06475989	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT06475989	Map
ID	Idaho Urologic Institute-Meridian	Meridian83642	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT06475989	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT06475989	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06475989	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT06475989	Map
IL	OSF Saint Anthony's Health Center	Alton62002	NCT06475989	Map
IL	Advocate Outpatient Center - Aurora	Aurora60506	NCT06475989	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT06475989	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT06475989	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT04485559	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT06712875	Map
IL	Cancer Treatment Centers of America-Chicago	Chicago60099	NCT02693535	Map
IL	Lurie Children's Hospital of Chicago	Chicago60611	NCT05849662	Map
IL	Northwestern University	Chicago60611	NCT06475989	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT06475989	Map
IL	University Of Chicago Medical Center	Chicago60637	NCT05874414	Map
IL	University of Illinois	Chicago60612	NCT06475989	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT06475989	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06475989	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT06475989	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT06475989	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06475989	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06475989	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06475989	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT06475989	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06475989	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT06475989	Map
IL	Condell Memorial Hospital	Libertyville60048	NCT06475989	Map
IL	SSM Health Good Samaritan	Mount Vernon62864	NCT06475989	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT06475989	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT06475989	Map
IL	Advocate Outpatient Center - Oak Lawn	Oak Lawn60453	NCT06475989	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06475989	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT06475989	Map
IL	Advocate High Tech Medical Park	Palos Heights60463	NCT06475989	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06475989	Map
IL	Memorial Hospital East	Shiloh62269	NCT06475989	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06475989	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT06475989	Map
IN	Community Health Network (The University of Texas MD Anderson Cancer Center)	Indianapolis46250	NCT02693535	Map
IN	Indiana University/Riley Hospital for Children	Indianapolis46202	NCT05849662	Map
IN	Riley Hospital for Children	Indianapolis46202	NCT04485559	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06475989	Map
IA	University of Iowa Healthcare Cancer Services Quad Cities	Bettendorf52722	NCT06475989	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT06475989	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06475989	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06475989	Map
IA	Mercy Cancer Center-West Lakes	Clive50325	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06475989	Map
IA	Heartland Oncology and Hematology LLP	Council Bluffs51503	NCT06475989	Map
IA	Methodist Jennie Edmundson Hospital	Council Bluffs51503	NCT06475989	Map
IA	Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ	Council Bluffs51503	NCT06475989	Map
IA	Greater Regional Medical Center	Creston50801	NCT06475989	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT06475989	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06475989	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06475989	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT06475989	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT06475989	Map
IA	UI Healthcare Mission Cancer and Blood - Pella	Pella50219	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06475989	Map
IA	Mercy Medical Center-West Lakes	West Des Moines50266	NCT06475989	Map
IA	The Iowa Clinic PC	West Des Moines50266	NCT06475989	Map
KS	Central Care Cancer Center - Garden City	Garden City67846	NCT06475989	Map
KS	Central Care Cancer Center - Great Bend	Great Bend67530	NCT06475989	Map
KS	Mercy Hospital Pittsburg	Pittsburg66762	NCT06475989	Map
KY	Markey Cancer Center	Lexington40536	NCT04903119	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT06475989	Map
KY	University of Louisville-James Graham Brown Cancer Center	Louisville40202	NCT03899155	Map
ME	Harold Alfond Center for Cancer Care	Augusta04330	NCT02693535	Map
ME	Jackson Laboratory - Maine Cancer Genomics Initiative	Augusta04330	NCT02693535	Map
ME	Waldo County General Hospital	Belfast04915	NCT02693535	Map
ME	SMHC Cancer Care and Blood Disorders -Biddeford	Biddeford04005	NCT02693535	Map
ME	Northern Light Cancer Care	Brewer04412	NCT02693535	Map
ME	Raish Peavey Haskell Children's Cancer and Treatment Center	Brewer04412	NCT02693535	Map
ME	MaineHealth Cancer Care -Brunswick	Brunswick04011	NCT02693535	Map
ME	New England Cancer Specialist	Kennebunk04043	NCT02693535	Map
ME	York Hopsital Oncology & Infusion Care in Kittery	Kittery03904	NCT02693535	Map
ME	Stephens Memorial Hospital	Norway04268	NCT02693535	Map
ME	Penobscot Bay Medical Center	Rockport04856	NCT02693535	Map
ME	SMHC Cancer Care and Blood Disorders -Sandford	Sanford04073	NCT02693535	Map
ME	Maine Children's Cancer Program	Scarborough04074	NCT02693535	Map
ME	Maine Medical Partner's Women's Health	Scarborough04074	NCT02693535	Map
ME	New England Cancer Specialist	Scarborough04074	NCT02693535	Map
ME	MaineHealth Cancer Care -South Portland	South Portland04106	NCT02693535	Map
ME	New England Cancer Specialist	Topsham04086	NCT02693535	Map
ME	York Hospital Oncology & Infusion Care in Wells	Wells04090	NCT02693535	Map
ME	York Hospital Oncology & Infusion Care in York	York Village03909	NCT02693535	Map
MD	John Hopkins Medical Center	Baltimore21287	NCT07110246	Map
MD	John Hopkins University	Baltimore21287	NCT04485559	Map
MD	Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center	Baltimore21287	NCT05372354	Map
MD	Sidney Kimmel Cancer Center at Johns Hopkins	Baltimore21231	NCT05849662	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT06475989	Map
MA	Dana_Farber Cancer Institute (DFCI)	Boston02215	NCT03899155	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05372354	Map
MI	MyMichigan Medical Center Gratiot	Alma48801	NCT06475989	Map
MI	MyMichigan Medical Center Alpena	Alpena49707	NCT06475989	Map
MI	C.S. Mott Children's Hospital	Ann Arbor48109	NCT05849662	Map
MI	Trinity Health Ann Arbor Hospital	Ann Arbor48106	NCT02693535	Map
MI	Trinity Health IHA - Obstetrics and Gynecology West Arbor	Ann Arbor48103	NCT06475989	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT06475989	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06475989	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT06475989	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06475989	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT06475989	Map
MI	Chelsea Hospital	Chelsea48118	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06475989	Map
MI	Hematology Oncology Consultants-Clarkston	Clarkston48346	NCT06475989	Map
MI	Newland Medical Associates-Clarkston	Clarkston48346	NCT06475989	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT02693535	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT06475989	Map
MI	Henry Ford River District Hospital	East China Township48054	NCT06475989	—
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06475989	Map
MI	Genesee Hematology Oncology PC	Flint48503	NCT06475989	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT02693535	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06475989	Map
MI	Hurley Medical Center	Flint48503	NCT06475989	Map
MI	MyMichigan Medical Center Gladwin	Gladwin48624	NCT06475989	Map
MI	Cancer Research Consortium of West Michigan	Grand Rapids49503	NCT02693535	Map
MI	START Mid West	Grand Rapids49546	NCT06804824	Map
MI	Henry Ford Saint John Hospital - Academic	Grosse Pointe Woods48236	NCT06475989	Map
MI	Henry Ford Saint John Hospital - Breast	Grosse Pointe Woods48236	NCT06475989	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT06475989	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT02693535	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06475989	Map
MI	Trinity Health Livonia Hospital	Livonia48154	NCT02693535	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06475989	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT06475989	Map
MI	Henry Ford Warren Hospital - Breast Macomb	Macomb48044	NCT06475989	Map
MI	MyMichigan Medical Center Midland	Midland48670	NCT06475989	Map
MI	MyMichigan Medical Center Mount Pleasant	Mount Pleasant48858	NCT06475989	Map
MI	Hope Cancer Center	Pontiac48341	NCT06475989	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT06475989	Map
MI	Newland Medical Associates-Pontiac	Pontiac48341	NCT06475989	Map
MI	Trinity Health Oakland Hospital	Pontiac48341	NCT02693535	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06475989	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT02693535	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT06475989	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT06475989	Map
MI	Michigan Cancer Research Consortium	Traverse City48341	NCT02693535	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT02693535	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT06475989	Map
MI	Henry Ford Madison Heights Hospital - Breast	Warren48093	NCT06475989	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT06475989	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06475989	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT06475989	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT06475989	Map
MN	Cambridge Medical Center	Cambridge55008	NCT06475989	Map
MN	Minnesota Oncology Hematology PA-Chaska	Chaska55318	NCT06475989	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06475989	Map
MN	Minnesota Oncology - Coon Rapids	Coon Rapids55433	NCT06475989	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06475989	Map
MN	Minnesota Oncology - Edina	Edina55435	NCT06475989	Map
MN	Fairview Clinics and Surgery Center Maple Grove	Maple Grove55369	NCT06475989	Map
MN	Minnesota Oncology - Maple Grove	Maple Grove55369	NCT06475989	Map
MN	Minnesota Oncology Hematology PA-Maplewood	Maplewood55109	NCT06475989	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT06475989	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06475989	Map
MN	Children's Minnesota	Minneapolis55404	NCT04485559	Map
MN	Health Partners Inc	Minneapolis55454	NCT06475989	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT06475989	Map
MN	Monticello Cancer Center	Monticello55362	NCT06475989	Map
MN	New Ulm Medical Center	New Ulm56073	NCT06475989	Map
MN	Fairview Northland Medical Center	Princeton55371	NCT06475989	Map
MN	North Memorial Medical Health Center	Robbinsdale55422	NCT06475989	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06475989	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06475989	Map
MN	Regions Hospital	Saint Paul55101	NCT06475989	Map
MN	United Hospital	Saint Paul55102	NCT06475989	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT06475989	Map
MN	Lakeview Hospital	Stillwater55082	NCT06475989	Map
MN	Sanford Thief River Falls Medical Center	Thief River Falls56701	NCT06475989	Map
MN	Ridgeview Medical Center	Waconia55387	NCT06475989	Map
MN	Rice Memorial Hospital	Willmar56201	NCT06475989	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT06475989	Map
MN	Sanford Cancer Center Worthington	Worthington56187	NCT06475989	Map
MN	Fairview Lakes Medical Center	Wyoming55092	NCT06475989	Map
MO	Mercy Oncology and Hematology - Clayton-Clarkson	Ballwin63011	NCT06475989	Map
MO	Central Care Cancer Center - Bolivar	Bolivar65613	NCT06475989	Map
MO	Cox Cancer Center Branson	Branson65616	NCT06475989	Map
MO	Mercy Cancer Center - Cape Girardeau	Cape Girardeau63703	NCT06475989	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06475989	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06475989	Map
MO	Freeman Health System	Joplin64804	NCT06475989	Map
MO	Mercy Hospital Joplin	Joplin64804	NCT06475989	Map
MO	Children's Mercy Hospital	Kansas City64108	NCT05849662	Map
MO	Lake Regional Hospital	Osage Beach65065	NCT06475989	Map
MO	Mercy Clinic-Rolla-Cancer and Hematology	Rolla65401	NCT06475989	Map
MO	Phelps Health Delbert Day Cancer Institute	Rolla65401	NCT06475989	Map
MO	Heartland Regional Medical Center	Saint Joseph64506	NCT06475989	Map
MO	CoxHealth South Hospital	Springfield65807	NCT06475989	Map
MO	Mercy Hospital Springfield	Springfield65804	NCT06475989	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT06475989	Map
MO	Mercy Hospital South	St Louis63128	NCT06475989	Map
MO	Mercy Infusion Center - Chippewa	St Louis63109	NCT06475989	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06475989	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06475989	Map
MO	St. Louis Children's Hospital Washington University in St. Louis	St Louis63110	NCT07110246	Map
MO	Washington University in St. Louis	St Louis63110	NCT04485559	Map
MO	Washington University School of Medicine	St Louis63110	NCT06475989	Map
MO	Mercy Hospital Washington	Washington63090	NCT06475989	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06475989	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06475989	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06475989	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06475989	Map
MT	Great Falls Clinic	Great Falls59405	NCT06475989	Map
MT	Hi-Line Sletten Cancer Center	Havre59501	NCT06475989	Map
MT	Benefis Helena Specialty Center	Helena59601	NCT06475989	Map
MT	Logan Health Medical Center	Kalispell59901	NCT06475989	Map
MT	Community Medical Center	Missoula59804	NCT06475989	Map
MT	Saint Patrick Hospital - Community Hospital	Missoula59802	NCT06475989	Map
NE	Nebraska Cancer Specialists/Oncology Hematology West PC - MECC	Omaha68114	NCT06475989	Map
NE	Nebraska Methodist Hospital	Omaha68114	NCT06475989	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT02693535	Map
NH	NH Oncology - Hematology, PA	Concord03103	NCT02693535	Map
NH	Solinsky Center for Cancer Care	Manchester03103	NCT02693535	Map
NH	New England Cancer Specialist	Portsmouth03801	NCT02693535	Map
NJ	Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07477457	Map
NJ	John Theurer Cancer Center at Hackensack UMC	Hackensack07601	NCT05372354	Map
NJ	Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center	Hackensack07601	NCT04485559	Map
NJ	Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)	Middletown07748	NCT07477457	Map
NJ	Memorial Sloan Kettering at Bergen (Limited Protocol Activities)	Montvale07645	NCT07477457	Map
NM	Lovelace Medical Center - Saint Joseph Square	Albuquerque87102	NCT02693535	Map
NM	Presbyterian Kaseman Hospital	Albuquerque87110	NCT02693535	Map
NM	The University of New Mexico Comprehensive Cancer Center	Albuquerque87131	NCT02693535	Map
NM	Memorial Medical Center	Las Cruces88011	NCT02693535	Map
NM	Presbyterian Rust Medical Center	Rio Rancho87124	NCT02693535	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT03899155	Map
NY	Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities)	Commack11725	NCT07477457	Map
NY	Memorial Sloan Kettering at Westchester (Limited Protocol Activities)	Harrison10604	NCT07477457	Map
NY	Northwell Health Monter Cancer Center	Lake Success11042	NCT02693535	Map
NY	NYU Langone Hematology Oncology Associates-Mineola	Mineola11501	NCT03899155	Map
NY	Northern Westchester Hospital	Mount Kisco10549	NCT02693535	Map
NY	Cohen Children's Medical Center	New Hyde Park11040	NCT02693535	Map
NY	Manhattan Eye, Ear, and Throat Hospital	New York10065	NCT02693535	Map
NY	Memorial Sloan Kettering Cancer Center	New York10021	NCT05372354	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05849662	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activites)	New York10065	NCT07477457	Map
NY	New York University	New York10016	NCT04485559	Map
NY	Staten Island University Hospital	New York10305	NCT02693535	Map
NY	Queens Cancer Center	Rego Park11374	NCT02693535	Map
NY	Phelps Hospital	Sleepy Hollow10591	NCT02693535	Map
NY	Memorial Sloan Kettering at Nassau (Limited Protocol Activities)	Uniondale11553	NCT07477457	Map
NC	Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT02693535	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT06475989	Map
NC	Atrium Health's Levine Cancer Institute	Charlotte28277	NCT02693535	Map
NC	Duke University Medical Center	Durham27710	NCT06475989	Map
NC	Duke University Medical Center	Durham27710	NCT07110246	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT06475989	Map
ND	Sanford Health- Bismarck	Bismarck58501	NCT02693535	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT06475989	Map
ND	Sanford Health- Fargo	Fargo58122	NCT02693535	Map
ND	Sanford Medical Center Fargo	Fargo58104	NCT06475989	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT06475989	Map
ND	Sanford South University Medical Center	Fargo58103	NCT06475989	Map
ND	Southpointe-Sanford Medical Center Fargo	Fargo58103	NCT06475989	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05849662	Map
OH	Oncology Hematology Care	Cincinnati45242	NCT03899155	Map
OH	University of Cincinnati Medical Center	Cincinnati45219	NCT02693535	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT03975231	Map
OH	The Ohio University	Columbus43210	NCT03899155	Map
OH	Kettering Health	Kettering45429	NCT02693535	Map
OH	West Chester Hospital	West Chester45069	NCT02693535	Map
OK	Cancer Centers of Southwest Oklahoma Research	Lawton73505	NCT06475989	Map
OK	Mercy Hospital Oklahoma City	Oklahoma City73120	NCT06475989	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06475989	Map
OR	Saint Alphonsus Cancer Care Center-Baker City	Baker City97814	NCT06475989	Map
OR	Saint Charles Health System	Bend97701	NCT06475989	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT06475989	Map
OR	Bay Area Hospital	Coos Bay97420	NCT06475989	Map
OR	Providence Hood River Memorial Hospital	Hood River97031	NCT06475989	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06475989	Map
OR	Saint Alphonsus Cancer Care Center-Ontario	Ontario97914	NCT06475989	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06475989	Map
OR	Oregon Health & Science University	Portland97239	NCT05849662	Map
OR	Oregon Health and Science University	Portland97239	NCT06475989	Map
OR	Providence Health & Services	Portland97213	NCT02693535	Map
OR	Providence Portland Medical Center	Portland97213	NCT06475989	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06475989	Map
OR	Saint Charles Health System-Redmond	Redmond97756	NCT06475989	Map
PA	Lehigh Valley Hospital - Cedar Crest	Allentown18103	NCT02693535	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT06475989	Map
PA	Lehigh Valley Hospital - Muhlenberg	Bethlehem18017	NCT06475989	Map
PA	Lehigh Valley Hospital- Muhlenberg	Bethlehem18017	NCT02693535	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT02693535	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT06475989	Map
PA	St. Luke's University Health Network	Easton18045	NCT04903119	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT06475989	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT02693535	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT06475989	Map
PA	Lancaster General Health	Lancaster17601	NCT03899155	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT04485559	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT05849662	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT02693535	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT06475989	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06475989	Map
RI	Smilow Cancer Hospital Care Center - Westerly	Westerly02891	NCT06475989	Map
SC	SC Cancer Specialists at St. Joseph's/Candler Bluffton	Bluffton29910	NCT02693535	Map
SC	St. Joseph's/Candler Smith	Bluffton29910	NCT02693535	Map
SC	Summit Cancer Care at St. Josph's/Candler Bluffton	Bluffton29910	NCT02693535	Map
SC	Medical University of South Carolina	Charleston29425	NCT06475989	Map
SC	South Carolina Cancer Specialists	Hilton Head Island29926	NCT02693535	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT06475989	Map
SD	Sanford Cancer Center Oncology Clinic and Pharmacy	Sioux Falls57104	NCT02693535	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT06475989	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT07110246	Map
TN	St. Jude Children's Research Hospital Memphis	Memphis38105	NCT05849662	Map
TN	Tennesse Oncology	Nashville37203	NCT03899155	Map
TN	Tennessee Oncology - Nashville / Sarah Cannon Research Institute	Nashville37203	NCT02693535	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT06475989	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT04903119	Map
TX	NEXT Austin	Austin78758	NCT06804824	Map
TX	University Of Texas Southwestern Medical Center	Dallas75235	NCT04485559	Map
TX	Cook Children's Health Care System	Fort Worth76104	NCT06582745	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT02693535	Map
TX	Univ of Texas-M.D. Anderson Cancer Center	Houston77030	NCT03975231	Map
TX	University of Texas, MD Anderson Cancer Center	Houston77030	NCT05874414	Map
TX	NEXT Dallas	Irving75039	NCT06804824	Map
TX	NEXT San Antonio	San Antonio78299	NCT06804824	Map
TX	START San Antonio	San Antonio78229	NCT06804824	Map
UT	Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center	Cedar City84720	NCT02693535	Map
UT	START Mountain	Ogden84401	NCT06804824	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06475989	Map
UT	Intermountain Healthcare	Salt Lake City84107	NCT02693535	Map
UT	Primary Children's Hospital	Salt Lake City84113	NCT05849662	Map
UT	University of Utah	Salt Lake City84112	NCT07110246	Map
UT	Dixie Regional Medical Center-River Road Campus	St. George84770	NCT02693535	Map
VA	University of Virginia Comprehensive Cancer Center	Charlottesville22908	NCT05874414	Map
VA	Inova Schar Cancer Institute	Fairfax22042	NCT02693535	Map
VA	NEXT Virginia	Fairfax22031	NCT06804824	Map
WA	Providence Regional Cancer System-Aberdeen	Aberdeen98520	NCT06475989	Map
WA	PeaceHealth Saint Joseph Medical Center	Bellingham98225	NCT06475989	Map
WA	Northwest Medical Specialties	Bonney Lake98391	NCT02693535	Map
WA	Providence Regional Cancer System-Centralia	Centralia98531	NCT06475989	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT06475989	Map
WA	Providence Regional Cancer Partnership	Everett98201	NCT06475989	Map
WA	Northwest Medical Specialties	Federal Way98003	NCT02693535	Map
WA	Northwest Medical Specialties	Gig Harbor98332	NCT02693535	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT06475989	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT06475989	Map
WA	Providence Regional Cancer System-Lacey	Lacey98503	NCT06475989	Map
WA	PeaceHealth Saint John Medical Center	Longview98632	NCT06475989	Map
WA	Skagit Regional Health Cancer Care Center	Mount Vernon98274	NCT06475989	Map
WA	Northwest Medical Specialties	Olympia98502	NCT02693535	Map
WA	Northwest Medical Specialties	Puyallup98373	NCT02693535	Map
WA	Seattle Children's Hospital	Seattle98105	NCT05849662	Map
WA	Swedish Cancer Institute	Seattle98104	NCT02693535	Map
WA	Swedish Medical Center-Ballard Campus	Seattle98107	NCT06475989	Map
WA	Swedish Medical Center-Cherry Hill	Seattle98122-5711	NCT06475989	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT06475989	Map
WA	PeaceHealth United General Medical Center	Sedro-Woolley98284	NCT06475989	Map
WA	Cancer Care Northwest - Spokane South	Spokane99202	NCT06475989	Map
WA	Cancer Care Northwest-North Spokane	Spokane99218	NCT06475989	Map
WA	Cancer Care Northwest-Valley	Spokane99216	NCT06475989	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT02693535	Map
WA	PeaceHealth Southwest Medical Center	Vancouver98664	NCT06475989	Map
WA	Providence Saint Mary Regional Cancer Center	Walla Walla99362	NCT06475989	Map
WI	Aurora Cancer Care - Burlington	Burlington53105	NCT02693535	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT06475989	Map
WI	Aurora Saint Luke's South Shore	Cudahy53110	NCT06475989	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT06475989	Map
WI	Aurora Health Care - Germantown Health Center	Germantown53022	NCT02693535	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT06475989	Map
WI	Aurora Cancer Care - Grafton	Grafton53024	NCT02693535	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT06475989	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT02693535	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT06475989	Map
WI	Aurora Cancer Care - Kenosha South	Kenosha53142	NCT02693535	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT06475989	Map
WI	Aurora Bay Area Medical Center	Marinette54143	NCT02693535	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT06475989	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT06475989	Map
WI	Aurora Cancer Care Milwaukee	Milwaukee53209	NCT02693535	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT06475989	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT06475989	Map
WI	Aurora Sinai Medical Center	Milwaukee53223	NCT02693535	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT06475989	Map
WI	Aurora St. Luke's Medical Center	Milwaukee53215	NCT02693535	Map
WI	Aurora West Allis Medical Center	Milwaukee53227	NCT02693535	Map
WI	Froedtert Hospital and the Medical College of Wisconsin	Milwaukee53226	NCT05874414	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT06475989	Map
WI	Cancer Center of Western Wisconsin	New Richmond54017	NCT06475989	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT02693535	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT06475989	Map
WI	Aurora Cancer Care - Racine	Racine53406	NCT02693535	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT06475989	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT06475989	Map
WI	Vince Lombardi Cancer Center	Sheboygan53081	NCT02693535	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT06475989	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT06475989	Map
WI	Aurora Medical Center in Summit	Summit53066	NCT02693535	—
WI	Aurora Medical Center in Summit	Summit53066	NCT06475989	—
WI	Vince Lombardi Cancer Clinic - Two Rivers	Two Rivers54241	NCT02693535	Map
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT06475989	Map
WI	Aurora Cancer Care - Milwaukee West	Wauwatosa53226	NCT02693535	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT06475989	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT06475989	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT06475989	Map
WY	Memorial Hospital of Laramie County	Cheyenne82001	NCT06475989	Map
WY	Billings Clinic-Cody	Cody82414	NCT06475989	Map

Browse Trametinib Trials by State

New York clinical trials Illinois clinical trials Wisconsin clinical trials Missouri clinical trials California clinical trials Florida clinical trials Alaska clinical trials Michigan clinical trials Tennessee clinical trials Maryland clinical trials

trametinibmelanomacancermetastatic melanomacolorectal cancerunresectable melanomaclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

What Is Trametinib?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Trametinib Development Timeline

Conditions Under Study

All Trametinib Clinical Trials (243)

Sponsors

Where to Participate: All Trametinib Trial Sites in the U.S. (519 sites across 45 states)

Browse Trametinib Trials by State